
Supplementary information

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

In the format provided by the authors and unedited

Supplementary table 1: Demographic characteristics of patients who died for the individual outcomes in the 1-28 days following a first or second dose of COVID-19 vaccine or SARS-CoV-2 infection amongst the vaccinated population in England from December 1 2020 until August 24 2021 (cells with * are suppressed).

	Deaths for myocarditis							Deaths for pericarditis						
	1-28 days post 1st dose			1-28 days post 2nd dose			1-28 days post test	1-28 days post 1st dose			1-28 days post 2nd dose			1-28 days post test
	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	Positive SARS-CoV-2 test	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	Positive SARS-CoV-2 test
Total number of people	31	15	0	5	10	0	*	*	*	0	*	*	0	0
Women	38.7 (12)	60.0 (9)	-	*	50.0 (5)	-	*	*	*	-	*	*	-	-
Men	58.1 (18)	40.0 (6)	-	*	50.0 (5)	-	*	*	*	-	*	*	-	-
Not recorded	3.2 (1)	0	-	*	0	-	0	0	0	-	0	0	-	-
Mean age (SD)	64.4 (17.7)	72.2 (16.8)	-	70.6 (4.8)	74.5 (19.3)	-	82.3 (10.6)	71.5 (6.0)	86.0 (.)	-	74.3 (16.8)	81.0 (.)	-	-
Days between deaths and exposure (mean, SD)	12.7 (7.8)	14.1 (7.6)	-	9.6 (6.9)	11.3 (5.2)	-	12.0 (7.8)	8.3 (3.0)	21.0 (.)	-	10.7 (9.6)	16.0 (.)	-	-
	Deaths for cardiac arrhythmia													

	1-28 days post 1st dose			1-28 days post 2nd dose			1-28 days post test						
	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	ChAdOx1nCoV-19 vaccine	BNT162b2 mRNA vaccine	mRNA-1273	Positive SARS-CoV-2 test						
Total number of people	904	755	0	478	524	0	131						
Women	54.1 (489)	47.7 (360)	-	53.6 (256)	46.8 (245)	-	50.4 (66)						
Men	45.4 (410)	51.7 (390)	-	45.6 (218)	52.9 (277)	-	48.9 (64)						
Not recorded	0.6 (5)	0.7 (5)	-	0.8 (4)	0.4 (2)	-	0.8 (1)						
Mean age (SD)	84.9 (9.6)	85.7 (7.4)	-	84.3 (9.8)	85.6 (7.6)	-	85.8 (6.8)						
Days between deaths and exposure (mean, SD)	14.5 (8.2)	14.1 (7.7)	-	15.0 (8.0)	15.1 (8.0)	-	14.5 (6.8)						

Supplementary table 2: Incidence rate ratios (IRR 95% CI) by sex for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed).

		ChAdOx1 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine		Positive SARS-CoV-2 test	
	Time period	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Women									
Myocarditis	Baseline	230	1.00	163	1.00	6	1.00	40	1.00
	-28 to -1 days: 1st dose/positive test	32	0.72 (0.48, 1.07)	15	0.54 (0.31, 0.93)	*	n/a	14	3.40 (1.80, 6.45)
	0 day: 1st dose/positive test	*	1.41 (0.35, 5.72)	*	1.96 (0.48, 7.95)	*	n/a	13	74.94 (38.98, 144.09)
	1-7 days: 1st dose/positive test	19	1.86 (1.13, 3.06)	11	1.31 (0.69, 2.48)	*	n/a	28	23.06 (13.79, 38.55)
	8-14 days: 1st dose/positive test	11	1.02 (0.55, 1.91)	13	1.55 (0.85, 2.81)	*	n/a	17	14.06 (7.77, 25.46)
	15-21 days: 1 st dose/positive test	14	1.26 (0.72, 2.22)	13	1.66 (0.92, 2.99)	*	n/a	7	6.09 (2.68, 13.82)
	22-28 days: 1st dose/positive test	14	1.30 (0.74, 2.28)	10	1.47 (0.76, 2.83)	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	18	0.51 (0.31, 0.84)	17	0.84 (0.49, 1.43)	*	n/a		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
	1-7 days: 2nd dose	*	0.22 (0.05, 0.88)	8	1.45 (0.70, 3.00)	*	n/a		
	8-14 days: 2nd dose	6	0.65 (0.28, 1.48)	9	1.62 (0.81, 3.23)	*	n/a		
	15-21 days: 2nd dose	5	0.54 (0.22, 1.33)	6	1.11 (0.48, 2.55)	*	n/a		
	22-28 days: 2nd dose	10	1.08 (0.56, 2.06)	*	0.74 (0.27, 2.01)	*	n/a		
Pericarditis	Baseline	205	1.00	142	1.00	*	1.00	29	1.00

	-28 to -1 days: 1st dose/positive test	23	0.58 (0.37, 0.91)	14	0.61 (0.35, 1.08)	*	n/a	8	3.20 (1.40, 7.31)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	5	52.31 (19.40, 141.05)
	1-7 days: 1st dose/positive test	3	0.27 (0.09, 0.87)	6	0.97 (0.42, 2.23)	*	n/a	5	7.95 (2.96, 21.31)
	8-14 days: 1st dose/positive test	10	0.88 (0.46, 1.70)	*	0.60 (0.22, 1.65)	*	n/a	*	6.19 (2.11, 18.18)
	15-21 days: 1 st dose/positive test	6	0.49 (0.22, 1.13)	*	0.46 (0.14, 1.45)	*	n/a	*	n/a
	22-28 days: 1st dose/positive test	8	0.63 (0.31, 1.30)	9	1.29 (0.65, 2.57)	*	n/a	*	2.41 (0.57, 10.22)
	-28 to -1 days: 2nd dose	12	0.26 (0.14, 0.47)	11	0.40 (0.21, 0.75)	*	n/a		
	0 day: 2nd dose	*	n/a	*	1.83 (0.45, 7.44)	*	n/a		
	1-7 days: 2nd dose	7	0.64 (0.30, 1.38)	5	0.67 (0.27, 1.65)	*	n/a		
	8-14 days: 2nd dose	9	0.81 (0.41, 1.61)	*	0.57 (0.21, 1.56)	*	n/a		
	15-21 days: 2nd dose	11	1.03 (0.55, 1.92)	9	1.26 (0.63, 2.52)	*	n/a		
	22-28 days: 2nd dose	5	0.50 (0.20, 1.22)	5	0.70 (0.28, 1.74)	*	n/a		
Cardiac arrhythmia	Baseline	56585	1.00	55963	1.00	758	1.00	8125	1.00
	-28 to -1 days: 1st dose/positive test	8174	0.75 (0.73, 0.77)	6097	0.69 (0.67, 0.71)	111	0.90 (0.74, 1.10)	3286	4.46 (4.27, 4.65)
	0 day: 1st dose/positive test	162	0.38 (0.33, 0.45)	117	0.33 (0.28, 0.40)	6	1.46 (0.65, 3.27)	1725	57.83 (54.81, 61.01)
	1-7 days: 1st dose/positive test	2844	0.94 (0.90, 0.98)	1878	0.75 (0.72, 0.79)	21	0.73 (0.47, 1.13)	1949	9.19 (8.73, 9.67)
	8-14 days: 1st dose/positive test	2870	0.91 (0.88, 0.95)	2258	0.87 (0.83, 0.91)	19	0.69 (0.44, 1.09)	1111	5.10 (4.78, 5.43)
	15-21 days: 1 st dose/positive test	3028	0.95 (0.91, 0.99)	2317	0.88 (0.84, 0.91)	19	0.76 (0.48, 1.20)	472	2.07 (1.89, 2.27)

	22-28 days: 1st dose/positive test	2909	0.90 (0.87, 0.94)	2202	0.86 (0.83, 0.90)	19	0.83 (0.53, 1.31)	381	1.59 (1.43, 1.76)
	-28 to -1 days: 2nd dose	8811	0.75 (0.73, 0.77)	7006	0.73 (0.71, 0.75)	22	0.72 (0.46, 1.11)		
	0 day: 2nd dose	118	0.28 (0.23, 0.33)	116	0.30 (0.25, 0.37)	*	n/a		
	1-7 days: 2nd dose	2527	0.86 (0.82, 0.89)	2272	0.85 (0.82, 0.89)	14	2.37 (1.38, 4.07)		
	8-14 days: 2nd dose	2759	0.95 (0.91, 0.99)	2503	0.94 (0.90, 0.98)	7	1.49 (0.70, 3.16)		
	15-21 days: 2nd dose	2856	1.00 (0.97, 1.04)	2595	0.98 (0.94, 1.02)	3	0.86 (0.28, 2.70)		
	22-28 days: 2nd dose	2730	0.98 (0.95, 1.02)	2537	0.97 (0.93, 1.01)	5	2.17 (0.89, 5.29)		
Men									
Myocarditis	Baseline	318	1.00	234	1.00	16	1.00	79	1.00
	-28 to -1 days: 1st dose/positive test	49	0.76 (0.55, 1.05)	34	0.91 (0.63, 1.32)	*	0.58 (0.12, 2.69)	18	2.54 (1.49, 4.34)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	23	80.42 (49.25, 131.32)
	1-7 days: 1st dose/positive test	28	1.73 (1.15, 2.60)	16	1.59 (0.95, 2.67)	7	11.76 (4.75, 29.13)	40	19.94 (13.27, 29.97)
	8-14 days: 1st dose/positive test	24	1.35 (0.87, 2.09)	10	0.98 (0.52, 1.87)	*	n/a	20	9.50 (5.72, 15.80)
	15-21 days: 1 st dose/positive test	16	0.89 (0.53, 1.50)	8	0.77 (0.38, 1.57)	*	n/a	11	4.94 (2.60, 9.40)
	22-28 days: 1st dose/positive test	15	0.82 (0.48, 1.40)	13	1.26 (0.71, 2.24)	*	n/a	10	4.15 (2.12, 8.12)
	-28 to -1 days: 2nd dose	40	0.77 (0.54, 1.09)	31	1.09 (0.73, 1.62)	*	3.47 (0.66, 18.17)		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
	1-7 days: 2nd dose	11	0.88 (0.47, 1.62)	15	2.06 (1.20, 3.54)	*	27.80 (6.39, 120.88)		
	8-14 days: 2nd dose	21	1.74 (1.10, 2.76)	6	0.87 (0.38, 1.99)	*	n/a		
	15-21 days: 2nd dose	14	1.20 (0.69, 2.08)	8	1.23 (0.60, 2.53)	*	n/a		
	22-28 days: 2nd dose	14	1.23 (0.71, 2.12)	8	1.27 (0.62, 2.62)	*	n/a		
	Pericarditis	Baseline	375	1.00	272	1.00	10	1.00	66
-28 to -1 days: 1st dose/positive test		41	0.53 (0.38, 0.75)	28	0.63 (0.42, 0.94)	*	1.93 (0.60, 6.23)	21	3.80 (2.26, 6.39)

	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	6	27.81 (11.84, 65.30)
	1-7 days: 1st dose/positive test	15	0.71 (0.42, 1.20)	5	0.40 (0.16, 0.97)	*	n/a	6	3.70 (1.58, 8.66)
	8-14 days: 1st dose/positive test	24	1.08 (0.71, 1.65)	5	0.39 (0.16, 0.95)	*	n/a	5	2.92 (1.16, 7.33)
	15-21 days: 1 st dose/positive test	17	0.73 (0.44, 1.20)	16	1.27 (0.76, 2.12)	*	n/a	*	1.70 (0.53, 5.46)
	22-28 days: 1st dose/positive test	18	0.76 (0.47, 1.23)	11	0.87 (0.47, 1.60)	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	46	0.51 (0.37, 0.71)	24	0.51 (0.33, 0.78)	*	n/a		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
	1-7 days: 2nd dose	30	1.36 (0.92, 2.00)	7	0.53 (0.25, 1.13)	*	n/a		
	8-14 days: 2nd dose	20	0.93 (0.58, 1.47)	12	0.92 (0.51, 1.66)	*	n/a		
	15-21 days: 2nd dose	25	1.18 (0.77, 1.79)	12	0.93 (0.52, 1.68)	*	n/a		
	22-28 days: 2nd dose	10	0.49 (0.26, 0.92)	21	1.70 (1.08, 2.69)	*	n/a		
Cardiac arrhythmia	Baseline	61748	1.00	57988	1.00	463	1.00	6994	1.00
	-28 to -1 days: 1st dose/positive test	9387	0.81 (0.79, 0.82)	6670	0.75 (0.73, 0.77)	73	0.91 (0.71, 1.17)	3332	5.24 (5.02, 5.48)
	0 day: 1st dose/positive test	127	0.29 (0.24, 0.34)	115	0.32 (0.27, 0.39)	*	1.12 (0.36, 3.48)	2122	83.82 (79.71, 88.15)
	1-7 days: 1st dose/positive test	3026	0.95 (0.92, 0.99)	2079	0.82 (0.78, 0.86)	17	0.93 (0.57, 1.51)	2644	14.70 (14.03, 15.40)
	8-14 days: 1st dose/positive test	3111	0.94 (0.91, 0.98)	2578	0.97 (0.93, 1.01)	21	1.19 (0.77, 1.85)	1531	8.28 (7.83, 8.76)
	15-21 days: 1 st dose/positive test	3213	0.95 (0.91, 0.98)	2654	0.97 (0.94, 1.01)	24	1.43 (0.95, 2.16)	494	2.57 (2.34, 2.81)
	22-28 days: 1st dose/positive test	3218	0.93 (0.90, 0.97)	2388	0.91 (0.87, 0.95)	16	1.01 (0.61, 1.67)	357	1.76 (1.58, 1.96)
	-28 to -1 days: 2nd dose	9784	0.76 (0.74, 0.78)	8004	0.78 (0.76, 0.80)	16	0.61 (0.36, 1.01)		
	0 day: 2nd dose	147	0.31 (0.27, 0.37)	141	0.34 (0.29, 0.41)	*	n/a		
	1-7 days: 2nd dose	2708	0.83 (0.80, 0.86)	2464	0.86 (0.82, 0.89)	8	1.48 (0.73, 3.01)		

	8-14 days: 2nd dose	3172	0.98 (0.95, 1.02)	2785	0.96 (0.92, 1.00)	6	1.31 (0.58, 2.97)		
	15-21 days: 2nd dose	3161	1.00 (0.96, 1.04)	2899	1.00 (0.96, 1.04)	*	0.83 (0.27, 2.62)		
	22-28 days: 2nd dose	3102	1.00 (0.97, 1.04)	2890	1.01 (0.97, 1.05)	*	0.78 (0.19, 3.16)		

Supplementary table 3a: Incidence rate ratios (IRR 95% CI) by age groups (older or younger than 40) for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed).

		ChAdOx1 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine		Positive SARS-CoV-2 test	
	Time period	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Age <40									
Myocarditis	Baseline	95	1.00	120	1.00	16	1.00	37	1.00
	-28 to -1 days: 1st dose/positive test	8	0.38 (0.18, 0.81)	15	0.96 (0.55, 1.68)	*	0.77 (0.17, 3.51)	7	1.75 (0.76, 4.05)
	0 day: 1st dose/positive test	*	n/a	*	3.30 (0.81, 13.50)	*	n/a	5	31.41 (11.91, 82.80)
	1-7 days: 1st dose/positive test	14	2.49 (1.36, 4.58)	14	3.16 (1.77, 5.66)	6	10.92 (4.09, 29.16)	10	9.06 (4.31, 19.02)
	8-14 days: 1st dose/positive test	*	0.34 (0.08, 1.41)	11	2.30 (1.20, 4.41)	*	n/a	*	n/a
	15-21 days: 1st dose/positive test	*	0.68 (0.24, 1.90)	5	1.11 (0.45, 2.77)	*	n/a	*	2.97 (0.90, 9.85)
	22-28 days: 1st dose/positive test	*	n/a	*	0.68 (0.21, 2.18)	*	n/a	*	2.67 (0.79, 8.99)
	-28 to -1 days: 2nd dose	5	0.39 (0.15, 0.99)	7	0.91 (0.41, 2.05)	*	4.62 (0.79, 26.97)		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		

	1-7 days: 2nd dose	*	0.60 (0.14, 2.49)	14	8.15 (4.37, 15.20)	*	44.43 (8.92, 221.24)		
	8-14 days: 2nd dose	11	3.24 (1.65, 6.39)	*	1.36 (0.32, 5.67)	*	n/a		
	15-21 days: 2nd dose	*	0.57 (0.14, 2.35)	*	1.59 (0.38, 6.64)	*	n/a		
	22-28 days: 2nd dose	6	1.63 (0.69, 3.85)	*	n/a	*	n/a		
Pericarditis	Baseline	57	1.00	107	1.00	11	1.00	26	1.00
	-28 to -1 days: 1st dose/positive test	7	0.46 (0.21, 1.04)	16	0.86 (0.50, 1.49)	*	1.77 (0.48, 6.57)	5	2.08 (0.76, 5.66)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	*	21.59 (4.96, 94.00)
	1-7 days: 1st dose/positive test	*	0.58 (0.14, 2.44)	*	0.81 (0.29, 2.23)	*	n/a	*	2.67 (0.62, 11.49)
	8-14 days: 1st dose/positive test	*	0.58 (0.14, 2.44)	*	0.43 (0.10, 1.76)	*	n/a	*	n/a
	15-21 days: 1st dose/positive test	*	n/a	6	1.38 (0.60, 3.21)	*	n/a	*	n/a
	22-28 days: 1st dose/positive test	*	0.59 (0.14, 2.47)	*	0.98 (0.35, 2.70)	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	6	0.58 (0.24, 1.39)	7	0.90 (0.40, 2.01)	*	n/a		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
	1-7 days: 2nd dose	6	2.25 (0.93, 5.48)	*	1.30 (0.40, 4.23)	*	n/a		
	8-14 days: 2nd dose	5	2.00 (0.77, 5.23)	*	1.43 (0.44, 4.65)	*	n/a		
	15-21 days: 2nd dose	*	1.77 (0.62, 5.07)	*	1.08 (0.26, 4.50)	*	n/a		
	22-28 days: 2nd dose	*	0.95 (0.22, 4.00)	*	1.18 (0.28, 4.97)	*	n/a		
Cardiac arrhythmia	Baseline	5520	1.00	11531	1.00	924	1.00	2290	1.00
	-28 to -1 days: 1st dose/positive test	1036	0.87 (0.81, 0.93)	1787	0.90 (0.86, 0.95)	147	1.00 (0.84, 1.19)	283	1.24 (1.09, 1.40)

	0 day: 1st dose/positive test	17	0.39 (0.24, 0.63)	25	0.36 (0.25, 0.54)	6	1.25 (0.56, 2.79)	189	21.63 (18.62, 25.14)
	1-7 days: 1st dose/positive test	352	1.15 (1.03, 1.28)	364	0.76 (0.69, 0.85)	29	0.88 (0.61, 1.27)	378	6.14 (5.50, 6.87)
	8-14 days: 1st dose/positive test	274	0.88 (0.77, 0.99)	459	0.98 (0.89, 1.07)	25	0.78 (0.53, 1.17)	258	4.14 (3.63, 4.72)
	15-21 days: 1 st dose/positive test	279	0.89 (0.79, 1.01)	405	0.89 (0.81, 0.99)	27	0.92 (0.63, 1.35)	118	1.82 (1.51, 2.19)
	22-28 days: 1st dose/positive test	267	0.85 (0.75, 0.96)	411	0.96 (0.87, 1.06)	27	1.01 (0.69, 1.49)	114	1.69 (1.40, 2.04)
	-28 to -1 days: 2nd dose	839	0.76 (0.71, 0.83)	659	0.76 (0.70, 0.82)	18	0.67 (0.42, 1.09)		
	0 day: 2nd dose	20	0.51 (0.33, 0.80)	15	0.46 (0.27, 0.76)	*	n/a		
	1-7 days: 2nd dose	256	0.96 (0.84, 1.09)	246	1.12 (0.98, 1.27)	10	2.09 (1.10, 3.94)		
	8-14 days: 2nd dose	268	1.03 (0.91, 1.17)	232	1.14 (1.00, 1.30)	5	1.38 (0.57, 3.36)		
	15-21 days: 2nd dose	248	0.98 (0.86, 1.12)	178	0.96 (0.83, 1.12)	*	n/a		
	22-28 days: 2nd dose	218	0.89 (0.78, 1.02)	146	0.87 (0.74, 1.03)	*	1.39 (0.34, 5.62)		
Age >= 40									
Myocarditis	Baseline	455	1.00	278	1.00	6	1.00	82	1.00
	-28 to -1 days: 1st dose/positive test	73	0.81 (0.62, 1.05)	34	0.70 (0.48, 1.03)	*	n/a	25	3.40 (2.12, 5.46)
	0 day: 1st dose/positive test	*	0.66 (0.16, 2.68)	*	n/a	*	n/a	31	100.44 (64.84, 155.60)
	1-7 days: 1st dose/positive test	33	1.49 (1.03, 2.17)	13	0.91 (0.51, 1.62)	*	n/a	58	26.08 (18.16, 37.44)
	8-14 days: 1st dose/positive test	33	1.38 (0.95, 2.01)	12	0.84 (0.46, 1.54)	*	n/a	36	15.61 (10.35, 23.54)
	15-21 days: 1 st dose/positive test	26	1.08 (0.71, 1.63)	16	1.11 (0.66, 1.88)	*	n/a	15	6.27 (3.58, 11.00)
	22-28 days: 1st dose/positive test	29	1.19 (0.81, 1.77)	20	1.49 (0.93, 2.40)	*	n/a	8	3.20 (1.54, 6.67)
	-28 to -1 days: 2nd dose	53	0.69 (0.51, 0.94)	41	0.91 (0.64, 1.29)	*	n/a		
	0 day: 2nd dose	*	0.72 (0.18, 2.92)	*	n/a	*	n/a		

	1-7 days: 2nd dose	11	0.58 (0.31, 1.06)	9	0.73 (0.37, 1.44)	*	n/a		
	8-14 days: 2nd dose	17	0.92 (0.56, 1.50)	13	1.04 (0.59, 1.83)	*	n/a		
	15-21 days: 2nd dose	17	0.95 (0.58, 1.56)	12	0.99 (0.55, 1.78)	*	n/a		
	22-28 days: 2nd dose	18	1.04 (0.64, 1.68)	12	1.01 (0.56, 1.83)	*	n/a		
Pericarditis	Baseline	524	1.00	307	1.00	*	1.00	69	1.00
	-28 to -1 days: 1st dose/positive test	57	0.59 (0.44, 0.79)	26	0.60 (0.39, 0.90)	*	2.90 (0.18, 46.58)	24	4.38 (2.68, 7.18)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	9	42.93 (20.99, 87.78)
	1-7 days: 1st dose/positive test	17	0.62 (0.38, 1.01)	7	0.56 (0.26, 1.20)	*	n/a	9	6.15 (3.01, 12.54)
	8-14 days: 1st dose/positive test	32	1.10 (0.76, 1.59)	7	0.52 (0.24, 1.11)	*	n/a	9	5.82 (2.86, 11.85)
	15-21 days: 1st dose/positive test	22	0.71 (0.46, 1.09)	13	0.94 (0.53, 1.67)	*	n/a	*	2.42 (0.88, 6.70)
	22-28 days: 1st dose/positive test	24	0.73 (0.48, 1.12)	16	1.10 (0.66, 1.85)	*	n/a	*	1.12 (0.27, 4.58)
	-28 to -1 days: 2nd dose	52	0.41 (0.30, 0.55)	28	0.41 (0.28, 0.62)	*	n/a		
	0 day: 2nd dose	*	n/a	*	1.07 (0.34, 3.35)	*	n/a		
	1-7 days: 2nd dose	31	1.00 (0.68, 1.45)	9	0.48 (0.24, 0.93)	*	n/a		
	8-14 days: 2nd dose	24	0.78 (0.51, 1.19)	13	0.71 (0.40, 1.24)	*	n/a		
	15-21 days: 2nd dose	32	1.05 (0.73, 1.53)	19	1.02 (0.64, 1.64)	*	n/a		
	22-28 days: 2nd dose	13	0.45 (0.26, 0.79)	24	1.33 (0.87, 2.03)	*	n/a		
Cardiac arrhythmia	Baseline	112836	1.00	102437	1.00	297	1.00	12829	1.00
	-28 to -1 days: 1st dose/positive test	16526	0.77 (0.76, 0.78)	10980	0.69 (0.68, 0.71)	37	0.64 (0.46, 0.91)	6335	5.49 (5.32, 5.67)
	0 day: 1st dose/positive test	272	0.33 (0.29, 0.37)	207	0.32 (0.28, 0.37)	*	1.50 (0.48, 4.70)	3658	78.56 (75.62, 81.61)
	1-7 days: 1st dose/positive test	5521	0.93 (0.91, 0.96)	3594	0.79 (0.76, 0.81)	9	0.66 (0.34, 1.27)	4215	12.72 (12.27, 13.19)
	8-14 days: 1st dose/positive test	5707	0.93 (0.90, 0.96)	4378	0.91 (0.88, 0.94)	15	1.13 (0.67, 1.90)	2385	7.00 (6.69, 7.32)

15-21 days: 1 st dose/positive test	5964	0.95 (0.93, 0.98)	4566	0.92 (0.90, 0.95)	16	1.23 (0.74, 2.05)	848	2.38 (2.22, 2.56)
22-28 days: 1st dose/positive test	5861	0.92 (0.90, 0.95)	4182	0.88 (0.85, 0.91)	8	0.64 (0.32, 1.30)	624	1.66 (1.54, 1.80)
-28 to -1 days: 2nd dose	17756	0.75 (0.74, 0.77)	14351	0.75 (0.73, 0.76)	20	0.62 (0.39, 0.98)		
0 day: 2nd dose	245	0.29 (0.25, 0.32)	242	0.32 (0.28, 0.36)	*	n/a		
1-7 days: 2nd dose	4980	0.84 (0.82, 0.86)	4491	0.84 (0.81, 0.86)	12	1.76 (0.98, 3.16)		
8-14 days: 2nd dose	5663	0.97 (0.94, 0.99)	5056	0.94 (0.91, 0.96)	8	1.34 (0.66, 2.72)		
15-21 days: 2nd dose	5771	1.01 (0.98, 1.03)	5317	0.99 (0.96, 1.02)	5	1.02 (0.42, 2.47)		
22-28 days: 2nd dose	5615	1.00 (0.98, 1.03)	5281	0.99 (0.96, 1.02)	5	1.37 (0.56, 3.35)		

Supplementary table 3b: Incidence rate ratios (IRR 95% CI) by age groups (16-29; 30-39; 40+) for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed).

		ChAdOx1 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine		Positive SARS-CoV-2 test	
	Time period	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Age 16-29									
Myocarditis	Baseline	43	1.00	61	1.00	9	1.00	19	1.00
	-28 to -1 days: 1st dose/positive test	5	0.52 (0.19, 1.38)	8	0.82 (0.38, 1.78)	*	1.27 (0.26, 6.33)	*	1.73 (0.57, 5.30)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	*	n/a
	1-28 days: 1st dose/positive test	9	1.01 (0.46, 2.22)	11	1.11 (0.56, 2.21)	6	5.20 (1.70, 15.94)	7	2.83 (1.14, 7.03)
	-28 to -1 days: 2nd dose	*	n/a	*	0.87 (0.26, 2.96)	*	n/a		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		

	1-28 days: 2nd dose	10	1.54 (0.70, 3.37)	8	2.88 (1.24, 6.72)	*	74.39 (5.28, 1048.75)		
Pericarditis	Baseline	29	1.00	58	1.00	5	1.00	19	1.00
	-28 to -1 days: 1st dose/positive test	*	0.41 (0.12, 1.42)	8	0.88 (0.40, 1.93)	*	n/a	5	2.58 (0.90, 7.38)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	*	n/a
	1-28 days: 1st dose/positive test	*	0.41 (0.12, 1.42)	6	0.82 (0.34, 1.98)	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	*	0.38 (0.09, 1.70)	*	1.00 (0.29, 3.49)	*	n/a		
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
	1-28 days: 2nd dose	9	2.20 (0.92, 5.25)	6	1.81 (0.69, 4.74)	*	n/a		
Cardiac arrhythmia	Baseline	2211	1.00	5832	1.00	479	1.00	1146	1.00
	-28 to -1 days: 1st dose/positive test	420	0.86 (0.77, 0.96)	827	0.88 (0.82, 0.95)	66	0.94 (0.73, 1.22)	148	1.27 (1.07, 1.52)
	0 day: 1st dose/positive test	11	0.62 (0.34, 1.12)	13	0.39 (0.23, 0.68)	*	1.29 (0.41, 4.01)	77	17.60 (13.94, 22.22)
	1-28 days: 1st dose/positive test	498	0.99 (0.89, 1.09)	810	0.94 (0.87, 1.02)	56	1.02 (0.77, 1.36)	333	2.66 (2.34, 3.01)
	-28 to -1 days: 2nd dose	365	0.84 (0.75, 0.95)	263	0.80 (0.70, 0.91)	*	0.78 (0.28, 2.20)		
	0 day: 2nd dose	11	0.72 (0.40, 1.31)	6	0.46 (0.21, 1.04)	*	n/a		
	1-28 days: 2nd dose	416	1.02 (0.92, 1.14)	315	0.99 (0.87, 1.11)	*	0.64 (0.15, 2.64)		
Age 30-39									
Myocarditis	Baseline	52	1.00	59	1.00	7	1.00	18	1.00
	-28 to -1 days: 1st dose/positive test	*	0.24 (0.07, 0.80)	7	1.15 (0.50, 2.65)	*	n/a	*	1.76 (0.49, 6.25)

Myocarditis	Baseline	455	1.00	278	1.00	6	1.00	82	1.00
	-28 to -1 days: 1st dose/positive test	73	0.76 (0.58, 1.00)	34	0.68 (0.47, 1.00)	*	n/a	25	3.22 (2.02, 5.15)
	0 day: 1st dose/positive test	*	0.66 (0.16, 2.67)	*	n/a	*	n/a	31	94.81 (61.39, 146.42)
	1-28 days: 1st dose/positive test	121	1.33 (1.06, 1.67)	61	1.12 (0.83, 1.52)	*	n/a	117	12.18 (9.01, 16.46)
	-28 to -1 days: 2nd dose	53	0.70 (0.51, 0.95)	41	0.93 (0.65, 1.32)	*	n/a		
	0 day: 2nd dose	*	0.73 (0.18, 2.95)	0	n/a	*	n/a		
	1-28 days: 2nd dose	63	0.87 (0.65, 1.15)	46	0.96 (0.69, 1.34)	*	2.23 (0.23, 21.46)		
Pericarditis	Baseline	524	1.00	307	1.00	*	1.00	69	1.00
	-28 to -1 days: 1st dose/positive test	57	0.59 (0.44, 0.78)	26	0.60 (0.39, 0.90)	*	n/a	24	4.30 (2.63, 7.03)
	0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	9	42.16 (20.65, 86.07)
	1-28 days: 1st dose/positive test	95	0.79 (0.62, 1.00)	43	0.80 (0.57, 1.12)	*	n/a	24	3.72 (2.30, 6.00)
	-28 to -1 days: 2nd dose	52	0.40 (0.30, 0.55)	28	0.41 (0.28, 0.61)	*	n/a		
	0 day: 2nd dose	*	n/a	*	1.07 (0.34, 3.35)	*	n/a		
	1-28 days: 2nd dose	100	0.82 (0.65, 1.04)	65	0.88 (0.66, 1.16)	*	n/a		
Cardiac arrhythmia	Baseline	112836	1.00	102437	1.00	297	1.00	12829	1.00
	-28 to -1 days: 1st dose/positive test	16526	0.75 (0.74, 0.76)	10980	0.68 (0.67, 0.70)	37	0.64 (0.46, 0.91)	6335	5.35 (5.18, 5.52)
	0 day: 1st dose/positive test	272	0.33 (0.29, 0.37)	207	0.32 (0.28, 0.37)	*	1.50 (0.48, 4.69)	3658	76.38 (73.54, 79.34)
	1-28 days: 1st dose/positive test	23053	0.94 (0.93, 0.96)	16720	0.88 (0.87, 0.90)	48	0.91 (0.67, 1.24)	8072	5.71 (5.54, 5.87)
	-28 to -1 days: 2nd dose	17756	0.76 (0.74, 0.77)	14351	0.75 (0.74, 0.77)	20	0.62 (0.39, 0.98)		

	0 day: 2nd dose	245	0.29 (0.25, 0.32)	242	0.32 (0.28, 0.36)	*	n/a		
	1-28 days: 2nd dose	22029	0.95 (0.94, 0.97)	20145	0.94 (0.93, 0.96)	30	1.40 (0.95, 2.07)		

Supplementary table 4: Incidence rate ratios (IRR 95% CI) for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed), including only people who did not have a SARS-CoV-2 positive test. Model for pericarditis does not converge with the mRNA-1273 vaccine.

		ChAdOx1 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine	
	Time period	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Myocarditis	Baseline	387	1.00	314	1.00	18	1.00
	-28 to -1 days: 1st dose/positive test	62	0.82 (0.62, 1.09)	42	0.84 (0.60, 1.17)	*	0.61 (0.14, 2.63)
	0 day: 1st dose/positive test	*	0.69 (0.17, 2.80)	*	1.53 (0.49, 4.78)	*	n/a
	1-7 days: 1st dose/positive test	38	1.91 (1.35, 2.70)	22	1.58 (1.02, 2.44)	5	6.30 (2.32, 17.13)
	8-14 days: 1st dose/positive test	24	1.15 (0.75, 1.76)	18	1.31 (0.81, 2.12)	*	n/a
	15-21 days: 1 st dose/positive test	22	1.02 (0.65, 1.58)	17	1.22 (0.75, 2.01)	*	n/a
	22-28 days: 1st dose/positive test	23	1.04 (0.67, 1.60)	17	1.28 (0.78, 2.10)	*	n/a
	-28 to -1 days: 2nd dose	53	0.71 (0.52, 0.96)	44	1.02 (0.73, 1.42)	*	1.90 (0.39, 9.31)
	0 day: 2nd dose	*	0.74 (0.18, 2.99)	*	n/a	*	n/a
	1-7 days: 2nd dose	11	0.59 (0.32, 1.08)	20	1.75 (1.10, 2.79)	*	19.86 (5.52, 71.47)
	8-14 days: 2nd dose	26	1.41 (0.93, 2.12)	15	1.34 (0.79, 2.27)	*	n/a
	15-21 days: 2nd dose	18	0.99 (0.61, 1.60)	13	1.20 (0.68, 2.12)	*	n/a
	22-28 days: 2nd dose	18	0.99 (0.61, 1.60)	11	1.04 (0.57, 1.93)	*	n/a
	1-28 days: 1st dose/positive test	107	1.27 (1.00, 1.60)	74	1.34 (1.03, 1.74)	7	2.37 (0.98, 5.75)

	1-28 days: 2nd dose	73	1.00 (0.76, 1.30)	59	1.35 (1.00, 1.82)	*	8.70 (2.35, 32.11)
Pericarditis	Baseline	501	1.00	376	1.00	-	-
	-28 to -1 days: 1st dose/positive test	57	0.56 (0.42, 0.75)	38	0.63 (0.45, 0.89)	-	-
	0 day: 1st dose/positive test	*	n/a	*	0.80 (0.20, 3.23)	-	-
	1-7 days: 1st dose/positive test	14	0.49 (0.29, 0.84)	9	0.52 (0.27, 1.02)	-	-
	8-14 days: 1st dose/positive test	29	0.96 (0.65, 1.41)	6	0.35 (0.16, 0.79)	-	-
	15-21 days: 1 st dose/positive test	19	0.59 (0.37, 0.94)	16	0.94 (0.57, 1.57)	-	-
	22-28 days: 1st dose/positive test	24	0.72 (0.48, 1.10)	16	0.90 (0.54, 1.49)	-	-
	-28 to -1 days: 2nd dose	51	0.40 (0.29, 0.54)	31	0.42 (0.29, 0.61)	-	-
	0 day: 2nd dose	*	n/a	*	0.65 (0.16, 2.64)	-	-
	1-7 days: 2nd dose	35	1.13 (0.80, 1.62)	12	0.58 (0.33, 1.04)	-	-
	8-14 days: 2nd dose	23	0.77 (0.50, 1.18)	14	0.70 (0.41, 1.21)	-	-
	15-21 days: 2nd dose	33	1.12 (0.78, 1.60)	21	1.06 (0.68, 1.67)	-	-
	22-28 days: 2nd dose	13	0.46 (0.26, 0.80)	25	1.32 (0.87, 1.99)	-	-
	1-28 days: 1st dose/positive test	86	0.69 (0.54, 0.88)	47	0.68 (0.50, 0.93)	-	-
	1-28 days: 2nd dose	104	0.87 (0.69, 1.09)	72	0.90 (0.69, 1.18)	-	-
Cardiac arrhythmia	Baseline	101126	1.00	105775	1.00	1012	1.00
	-28 to -1 days: 1st dose/positive test	15105	0.80 (0.79, 0.82)	11577	0.74 (0.72, 0.75)	167	0.92 (0.78, 1.08)
	0 day: 1st dose/positive test	244	0.33 (0.29, 0.37)	202	0.32 (0.28, 0.37)	8	1.30 (0.65, 2.61)
	1-7 days: 1st dose/positive test	4945	0.92 (0.90, 0.95)	3276	0.75 (0.72, 0.77)	31	0.74 (0.52, 1.06)
	8-14 days: 1st dose/positive test	5087	0.91 (0.89, 0.94)	3999	0.88 (0.86, 0.91)	38	0.95 (0.69, 1.32)
	15-21 days: 1 st dose/positive test	5442	0.95 (0.92, 0.97)	4286	0.91 (0.88, 0.94)	39	1.04 (0.75, 1.43)
	22-28 days: 1st dose/positive test	5509	0.93 (0.90, 0.95)	4117	0.89 (0.86, 0.92)	32	0.92 (0.65, 1.31)
	-28 to -1 days: 2nd dose	17321	0.76 (0.74, 0.77)	14319	0.75 (0.73, 0.76)	35	0.65 (0.46, 0.92)
	0 day: 2nd dose	249	0.30 (0.26, 0.34)	242	0.32 (0.28, 0.36)	*	n/a

1-7 days: 2nd dose	4837	0.84 (0.81, 0.86)	4479	0.84 (0.82, 0.87)	22	2.06 (1.34, 3.17)
8-14 days: 2nd dose	5515	0.97 (0.94, 0.99)	5047	0.94 (0.92, 0.97)	13	1.48 (0.85, 2.59)
15-21 days: 2nd dose	5606	1.00 (0.97, 1.03)	5240	0.98 (0.95, 1.01)	6	0.90 (0.40, 2.01)
22-28 days: 2nd dose	5456	1.00 (0.97, 1.03)	5201	0.98 (0.96, 1.01)	7	1.52 (0.72, 3.22)
1-28 days: 1st dose/positive test	20983	0.93 (0.91, 0.94)	15678	0.86 (0.85, 0.88)	140	0.90 (0.76, 1.08)
1-28 days: 2nd dose	21414	0.95 (0.93, 0.96)	19967	0.94 (0.93, 0.96)	48	1.56 (1.15, 2.12)

Supplementary table 5: Incidence rate ratios (IRR 95% CI) for the outcomes in 1-28 days risk periods immediately before and after exposure to vaccination, adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed), including only people who had a SARS-CoV-2 positive test result prior vaccination. Numbers of events in those vaccinated with mRNA-1273 vaccine were too small for meaningful results.

	Time period	ChAdOx1 vaccine		BNT162b2 mRNA vaccine		Positive SARS-CoV-2 test	
		events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Myocarditis	Baseline	145	1.00	66	1.00	95	1.00
	-28 to -1 days: 1st dose/positive test	19	0.52 (0.31, 0.88)	7	0.49 (0.21, 1.14)	25	1.63 (0.96, 2.78)
	0 day: 1st dose/positive test	*	n/a	*	n/a	23	38.14 (22.32, 65.18)
	1-28 days: 1st dose/positive test	18	1.09 (0.63, 1.91)	7	0.96 (0.42, 2.20)	106	6.59 (4.54, 9.56)
	-28 to -1 days: 2nd dose	*	0.35 (0.12, 0.99)	*	0.90 (0.31, 2.63)		
	0 day: 2nd dose	*	n/a	*	n/a		
	1-28 days: 2nd dose	9	0.91 (0.43, 1.94)	*	0.52 (0.12, 2.23)		
Pericarditis	Baseline	72	1.00	32	1.00	79	1.00
	-28 to -1 days: 1st dose/positive test	7	0.50 (0.22, 1.14)	*	0.54 (0.16, 1.81)	24	3.38 (1.80, 6.34)
	0 day: 1st dose/positive test	*	n/a	*	n/a	6	19.96 (7.89, 50.45)
	1-28 days: 1st dose/positive test	11	1.02 (0.50, 2.07)	7	1.43 (0.61, 3.36)	19	2.12 (1.15, 3.91)
	-28 to -1 days: 2nd dose	*	0.31 (0.09, 1.03)	*	1.52 (0.49, 4.70)		

	0 day: 2nd dose	*	n/a	*	n/a		
	1-28 days: 2nd dose	11	1.10 (0.54, 2.24)	*	n/a		
Cardiac arrhythmia	Baseline	14933	1.00	5895	1.00	10928	1.00
	-28 to -1 days: 1st dose/positive test	2025	0.55 (0.52, 0.58)	883	0.61 (0.56, 0.66)	4120	2.78 (2.64, 2.91)
	0 day: 1st dose/positive test	24	0.29 (0.19, 0.43)	15	0.41 (0.25, 0.68)	2402	39.09 (37.03, 41.25)
	1-28 days: 1st dose/positive test	1559	0.78 (0.74, 0.83)	694	0.81 (0.74, 0.88)	6761	4.05 (3.89, 4.22)
	-28 to -1 days: 2nd dose	1008	0.70 (0.65, 0.75)	462	0.78 (0.71, 0.87)		
	0 day: 2nd dose	11	0.21 (0.12, 0.39)	6	0.27 (0.12, 0.61)		
	1-28 days: 2nd dose	1269	0.95 (0.89, 1.01)	580	1.02 (0.93, 1.12)		

Supplementary table 6: Incidence rate ratios (IRR 95% CI) for subgroups of arrhythmia in pre-defined risk periods immediately before and after exposure to vaccination and before and after a Positive SARS-CoV-2 test result, adjusted for calendar time from December 1 2020 until August 24 2021, 2021 (cells with < 5 are suppressed).

	Time period	ChAdOx1 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine		Positive SARS-CoV-2 test	
		events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Atrial fibrillation and flutter	Baseline	69651	1.00	69639	1.00	143	1.00	7641	1.00
	-28 to -1 days: 1st dose/positive test	9620	0.74 (0.72, 0.75)	7344	0.68 (0.67, 0.70)	29	1.17 (0.78, 1.75)	4335	6.32 (6.08, 6.58)
	0 day: 1st dose/positive test	157	0.31 (0.27, 0.36)	129	0.30 (0.25, 0.35)	*	2.36 (0.58, 9.53)	2327	83.39 (79.47, 87.51)
	1-7 days: 1st dose/positive test	3249	0.89 (0.86, 0.93)	2474	0.79 (0.76, 0.83)	*	0.69 (0.26, 1.87)	2412	12.17 (11.61, 12.76)
	8-14 days: 1st dose/positive test	3465	0.92 (0.89, 0.95)	3003	0.92 (0.89, 0.96)	6	1.08 (0.48, 2.45)	1203	5.92 (5.56, 6.29)
	15-21 days: 1st dose/positive test	3565	0.93 (0.90, 0.96)	3061	0.91 (0.88, 0.95)	11	2.06 (1.11, 3.82)	464	2.18 (1.99, 2.40)
	22-28 days: 1st dose/positive test	3579	0.92 (0.89, 0.95)	2806	0.88 (0.84, 0.91)	5	0.85 (0.31, 2.30)	341	1.52 (1.36, 1.70)
	-28 to -1 days: 2nd dose	10507	0.72 (0.70, 0.74)	9401	0.73 (0.71, 0.74)	8	0.83 (0.40, 1.73)		

	1-28 days: 1st dose/positive test	7133	0.94 (0.91, 0.97)	5352	0.86 (0.83, 0.89)	15	0.73 (0.42, 1.25)	2290	4.65 (4.42, 4.90)	
	1-28 days: 2nd dose	6832	0.94 (0.92, 0.97)	6678	0.94 (0.91, 0.97)	*	0.87 (0.31, 2.41)			
Ventricular tachycardia	Baseline	2655	1.00	2184	1.00	12	1.00	344	1.00	
	-28 to -1 days: 1st dose/positive test	419	0.83 (0.74, 0.93)	225	0.69 (0.60, 0.80)	*	1.37 (0.38, 4.91)	120	4.03 (3.24, 5.01)	
	0 day: 1st dose/positive test	*	0.10 (0.02, 0.40)	6	0.45 (0.20, 1.01)	*	n/a	50	40.91 (30.22, 55.39)	
	1-7 days: 1st dose/positive test	133	0.92 (0.77, 1.11)	72	0.76 (0.59, 0.96)	*	n/a	42	4.84 (3.50, 6.71)	
	8-14 days:1st dose/positive test	133	0.89 (0.75, 1.07)	92	0.92 (0.74, 1.14)	*	4.08 (0.90, 18.52)	16	1.81 (1.09, 3.00)	
	15-21 days: 1st dose/positive test	177	1.15 (0.98, 1.35)	94	0.92 (0.74, 1.14)	*	n/a	23	2.53 (1.65, 3.87)	
	22-28 days: 1st dose/positive test	152	0.97 (0.82, 1.15)	111	1.06 (0.87, 1.29)	*	n/a	14	1.47 (0.86, 2.52)	
	-28 to -1 days: 2nd dose	445	0.74 (0.67, 0.83)	282	0.67 (0.58, 0.76)	*	n/a			
	0 day: 2nd dose	7	0.32 (0.15, 0.68)	*	0.12 (0.03, 0.49)	*	n/a			
	1-7 days: 2nd dose	119	0.80 (0.66, 0.97)	109	0.96 (0.78, 1.16)	*	n/a			
	8-14 days: 2nd dose	139	0.96 (0.80, 1.14)	119	1.03 (0.85, 1.25)	*	n/a			
	15-21 days: 2nd dose	150	1.06 (0.89, 1.25)	106	0.94 (0.77, 1.14)	*	n/a			
	22-28 days: 2nd dose	155	1.13 (0.96, 1.34)	103	0.93 (0.76, 1.14)	*	n/a			
		1-28 days: 1st dose/positive test	595	0.99 (0.89, 1.09)	369	0.92 (0.82, 1.04)	*	2.11 (0.67, 6.66)	95	2.64 (2.10, 3.34)
	1-28 days: 2nd dose	563	0.98 (0.89, 1.08)	437	0.97 (0.87, 1.08)	*	n/a			
Ventricular fibrillation	Baseline	1061	1.00	721	1.00	7	1.00	103	1.00	
	-28 to -1 days: 1st dose/positive test	150	0.69 (0.57, 0.83)	73	0.65 (0.50, 0.84)	*	n/a	43	5.02 (3.45, 7.30)	

	22-28 days: 1st dose/positive test	2119	0.90 (0.86, 0.94)	1427	0.86 (0.81, 0.90)	28	0.86 (0.58, 1.28)	398	1.87 (1.69, 2.07)
	-28 to -1 days: 2nd dose	6734	0.79 (0.77, 0.81)	4510	0.77 (0.75, 0.80)	30	0.67 (0.46, 0.97)		
	0 day: 2nd dose	85	0.27 (0.22, 0.34)	70	0.31 (0.24, 0.39)	*	n/a		
	1-7 days: 2nd dose	1887	0.88 (0.84, 0.92)	1401	0.88 (0.84, 0.93)	21	2.32 (1.49, 3.62)		
	8-14 days: 2nd dose	2027	0.95 (0.91, 1.00)	1540	0.97 (0.92, 1.02)	11	1.50 (0.82, 2.74)		
	15-21 days: 2nd dose	2130	1.03 (0.98, 1.07)	1519	0.97 (0.92, 1.02)	5	0.90 (0.37, 2.19)		
	22-28 days: 2nd dose	2025	1.00 (0.96, 1.05)	1487	0.97 (0.92, 1.02)	5	1.32 (0.54, 3.20)		
	1-28 days: 1st dose/positive test	8601	0.95 (0.92, 0.97)	5616	0.84 (0.82, 0.87)	120	0.82 (0.67, 0.99)	3674	4.60 (4.42, 4.79)
	1-28 days: 2nd dose	8069	0.96 (0.94, 0.99)	5947	0.95 (0.92, 0.98)	42	1.64 (1.18, 2.27)		

Supplementary Table 7: Incidence rate ratios (IRR 95% CI) for celiac disease (negative control) and anaphylaxis (positive control) in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 result, adjusted for calendar time from December 1 2020 to August 24 2021 (cells with < 5 are suppressed). Model for anaphylaxis with mRNA-1273 vaccine does not converge.

Group	Time period	Anaphylaxis (positive control)		Celiac disease (negative control)	
		events	IRR (95% CI)	events	IRR (95% CI)
ChAdOx1 vaccine	Baseline	726	1.00	3889	1.00
	-28 to -1 days: 1st dose	110	0.78 (0.63, 0.96)	718	0.96 (0.88, 1.05)
	0 day: 1st dose	63	11.83 (9.05, 15.47)	*	0.07 (0.02, 0.28)
	1-7 days: 1st dose	60	1.60 (1.22, 2.11)	166	0.83 (0.71, 0.97)
	8-14 days: 1st dose	29	0.76 (0.52, 1.10)	211	1.03 (0.90, 1.19)
	15-21 days: 1 st dose	43	1.09 (0.79, 1.49)	201	0.97 (0.84, 1.12)
	22-28 days: 1st dose	35	0.87 (0.62, 1.24)	205	0.97 (0.84, 1.12)
	-28 to -1 days: 2nd dose	137	0.93 (0.76, 1.13)	756	0.91 (0.84, 0.99)
	0 day: 2nd dose	16	2.97 (1.80, 4.89)	10	0.33 (0.18, 0.61)

	1-7 days: 2nd dose	40	1.06 (0.77, 1.47)	179	0.85 (0.73, 0.99)
	8-14 days: 2nd dose	40	1.06 (0.77, 1.47)	226	1.07 (0.94, 1.23)
	15-21 days: 2nd dose	34	0.92 (0.65, 1.30)	251	1.20 (1.05, 1.36)
	22-28 days: 2nd dose	50	1.39 (1.03, 1.86)	200	0.96 (0.83, 1.11)
	1-28 days: 1st dose	167	1.08 (0.90, 1.29)	783	0.95 (0.88, 1.04)
	1-28 days: 2nd dose	164	1.11 (0.92, 1.33)	856	1.02 (0.94, 1.10)
BNT162b2 mRNA vaccine	Baseline	521	1.00	3477	1.00
	-28 to -1 days: 1st dose	62	0.71 (0.54, 0.93)	555	0.95 (0.86, 1.04)
	0 day: 1st dose	39	12.20 (8.78, 16.95)	7	0.32 (0.15, 0.66)
	1-7 days: 1st dose	33	1.46 (1.02, 2.08)	120	0.77 (0.64, 0.93)
	8-14 days: 1st dose	27	1.19 (0.81, 1.76)	145	0.92 (0.77, 1.08)
	15-21 days: 1 st dose	25	1.14 (0.76, 1.71)	139	0.86 (0.72, 1.02)
	22-28 days: 1st dose	20	0.94 (0.60, 1.47)	147	0.91 (0.77, 1.08)
	-28 to -1 days: 2nd dose	52	0.94 (0.69, 1.26)	580	0.97 (0.89, 1.07)
	0 day: 2nd dose	11	5.00 (2.73, 9.15)	6	0.26 (0.12, 0.58)
	1-7 days: 2nd dose	22	1.44 (0.93, 2.23)	148	0.93 (0.78, 1.09)
	8-14 days: 2nd dose	17	1.14 (0.70, 1.87)	165	1.03 (0.88, 1.21)
	15-21 days: 2nd dose	19	1.32 (0.82, 2.10)	174	1.11 (0.95, 1.30)
	22-28 days: 2nd dose	15	1.07 (0.64, 1.81)	159	1.03 (0.88, 1.21)
	1-28 days: 1st dose	105	1.18 (0.95, 1.47)	551	0.87 (0.79, 0.96)
	1-28 days: 2nd dose	73	1.26 (0.97, 1.63)	646	1.03 (0.94, 1.12)
mRNA-1273 vaccine	Baseline	-	-	78	1.00
	-28 to -1 days: 1st dose	-	-	15	1.06 (0.61, 1.84)
	0 day: 1st dose	-	-	*	n/a
	1-7 days: 1st dose	-	-	*	n/a

	8-14 days: 1st dose	-	-	*	1.23 (0.45, 3.37)
	15-21 days: 1 st dose	-	-	5	1.53 (0.62, 3.80)
	22-28 days: 1st dose	-	-	*	1.49 (0.54, 4.10)
	-28 to -1 days: 2nd dose	-	-	8	1.42 (0.66, 3.08)
	0 day: 2nd dose	-	-	*	n/a
	1-7 days: 2nd dose	-	-	*	n/a
	8-14 days: 2nd dose	-	-	*	n/a
	15-21 days: 2nd dose	-	-	*	n/a
	22-28 days: 2nd dose	-	-	*	n/a
	1-28 days: 1st dose	-	-	15	1.11 (0.62, 1.96)
	1-28 days: 2nd dose	-	-	*	n/a
SARS-CoV-2	Baseline	187	1.00	621	1.00
	-28 to -1 days: positive test	23	1.30 (0.83, 2.02)	111	1.79 (1.46, 2.21)
	0 day: positive test	14	21.51 (12.36, 37.45)	51	22.12 (16.57, 29.53)
	1-7 days: positive test	10	2.28 (1.20, 4.33)	71	4.39 (3.42, 5.63)
	8-14 days: positive test	*	0.70 (0.22, 2.19)	55	3.33 (2.52, 4.40)
	15-21 days: positive test	*	0.68 (0.22, 2.14)	26	1.54 (1.04, 2.29)
	22-28 days: positive test	8	1.75 (0.86, 3.58)	22	1.25 (0.82, 1.92)
	1-28 days: positive test	24	1.35 (0.87, 2.08)	174	2.59 (2.18, 3.07)

Supplementary table 8a: Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to vaccination, adjusted for calendar time from December 1 2020 to August 24 2021. Comparisons between different sensitivity analyses (cells with < 5 are suppressed).

		Sensitivity 1*	Sensitivity 2*	Sensitivity 3*	Sensitivity 4*	Sensitivity 5*
--	--	----------------	----------------	----------------	----------------	----------------

		events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	
Myocarditis												
ChAdOx1 vaccine	Baseline	523	1.00	286	1.00	535	1.00	359	1.00	550	1.00	
	-28 to -1 days: 1st dose	81	0.80 (0.62, 1.03)	-	-	81	0.74 (0.58, 0.95)	81	0.74 (0.58, 0.96)	81	0.70 (0.54, 0.90)	
	0 day: 1st dose	*	n/a	*	0.46 (0.11, 1.89)	*	0.55 (0.14, 2.19)	*	0.56 (0.14, 2.24)	*	n/a	
	1-7 days: 1st dose	39	1.61 (1.14, 2.27)	47	1.55 (1.07, 2.24)	47	1.77 (1.29, 2.42)	45	1.72 (1.24, 2.38)	*	n/a	
	8-14 days: 1st dose	25	0.97 (0.64, 1.47)	35	1.11 (0.74, 1.65)	35	1.22 (0.85, 1.75)	34	1.22 (0.84, 1.77)	*	n/a	
	15-21 days: 1 st dose	22	0.83 (0.54, 1.29)	30	0.96 (0.63, 1.44)	30	1.03 (0.71, 1.51)	30	1.07 (0.73, 1.59)	*	n/a	
	22-28 days: 1st dose	25	0.95 (0.63, 1.44)	30	0.98 (0.65, 1.46)	30	1.03 (0.71, 1.51)	27	0.98 (0.65, 1.47)	*	n/a	
	-28 to -1 days: 2nd dose	58	0.66 (0.49, 0.88)	58	0.68 (0.50, 0.92)	58	0.65 (0.49, 0.87)	41	0.68 (0.47, 0.97)	58	0.58 (0.43, 0.78)	
	0 day: 2nd dose	*	0.64 (0.16, 2.56)	*	0.66 (0.16, 2.67)	*	0.64 (0.16, 2.56)	*	1.33 (0.33, 5.42)	*	0.57 (0.14, 2.30)	
	1-7 days: 2nd dose	11	0.50 (0.27, 0.92)	13	0.62 (0.35, 1.10)	13	0.60 (0.34, 1.05)	7	0.73 (0.33, 1.59)	13	0.54 (0.31, 0.94)	
	8-14 days: 2nd dose	26	1.20 (0.80, 1.80)	28	1.37 (0.92, 2.05)	28	1.31 (0.88, 1.94)	9	1.16 (0.58, 2.35)	28	1.18 (0.79, 1.74)	
	15-21 days: 2nd dose	18	0.84 (0.52, 1.36)	19	0.97 (0.60, 1.55)	19	0.91 (0.57, 1.45)	8	1.31 (0.62, 2.76)	19	0.82 (0.52, 1.31)	
	22-28 days: 2nd dose	24	1.13 (0.74, 1.73)	24	1.25 (0.81, 1.91)	23	1.12 (0.73, 1.71)	6	1.36 (0.58, 3.21)	24	1.06 (0.70, 1.61)	
		1-28 days: 1st dose	111	1.11 (0.88, 1.39)	142	1.15 (0.89, 1.50)	142	1.29 (1.05, 1.59)	136	1.28 (1.03, 1.60)	-	-
	1-28 days: 2nd dose	79	0.92 (0.71, 1.19)	84	1.05 (0.81, 1.36)	83	0.99 (0.77, 1.27)	30	1.09 (0.70, 1.69)	84	0.90 (0.70, 1.15)	
	Baseline	374	1.00	225	1.00	387	1.00	215	1.00	398	1.00	

BNT162b2 mRNA vaccine	-28 to -1 days: 1st dose	49	0.79 (0.58, 1.08)			49	0.75 (0.55, 1.02)	40	0.71 (0.50, 1.02)	49	0.74 (0.54, 1.00)
	0 day: 1st dose	*	0.89 (0.22, 3.56)	*	0.89 (0.27, 2.89)	*	1.25 (0.40, 3.89)	*	1.50 (0.48, 4.70)	*	n/a
	1-7 days: 1st dose	23	1.34 (0.87, 2.07)	27	1.01 (0.62, 1.65)	27	1.46 (0.98, 2.19)	16	1.05 (0.62, 1.78)	*	n/a
	8-14 days: 1st dose	20	1.17 (0.74, 1.85)	23	0.85 (0.51, 1.41)	23	1.24 (0.81, 1.92)	17	1.12 (0.66, 1.87)	*	n/a
	15-21 days: 1 st dose	17	1.01 (0.61, 1.65)	21	0.83 (0.50, 1.37)	21	1.15 (0.74, 1.81)	16	1.02 (0.60, 1.73)	*	n/a
	22-28 days: 1st dose	19	1.19 (0.75, 1.91)	23	1.03 (0.64, 1.65)	23	1.35 (0.88, 2.07)	18	1.22 (0.74, 2.02)	*	n/a
	-28 to -1 days: 2nd dose	48	0.98 (0.71, 1.34)	48	0.91 (0.65, 1.29)	48	0.97 (0.71, 1.33)	45	0.98 (0.69, 1.41)	48	0.85 (0.62, 1.17)
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 2nd dose	21	1.63 (1.03, 2.56)	23	1.63 (1.03, 2.56)	22	1.70 (1.09, 2.65)	12	1.07 (0.59, 1.97)	23	1.57 (1.02, 2.43)
	8-14 days: 2nd dose	11	0.87 (0.47, 1.59)	15	1.13 (0.66, 1.93)	15	1.19 (0.70, 2.02)	12	1.21 (0.66, 2.22)	15	1.05 (0.62, 1.78)
	15-21 days: 2nd dose	10	0.83 (0.44, 1.58)	14	1.14 (0.65, 1.98)	14	1.18 (0.68, 2.03)	9	1.03 (0.52, 2.07)	14	1.03 (0.60, 1.77)
	22-28 days: 2nd dose	12	1.03 (0.57, 1.85)	12	1.03 (0.57, 1.86)	12	1.04 (0.58, 1.86)	8	1.11 (0.53, 2.31)	12	0.91 (0.51, 1.63)
		1-28 days: 1st dose	79	1.20 (0.93, 1.54)	94	0.91 (0.66, 1.27)	94	1.33 (1.05, 1.68)	67	1.13 (0.84, 1.53)	-
	1-28 days: 2nd dose	54	1.11 (0.82, 1.51)	64	1.25 (0.92, 1.69)	63	1.30 (0.98, 1.74)	41	1.13 (0.78, 1.66)	64	1.16 (0.87, 1.54)
mRNA-1273 vaccine	Baseline	22	1.00	*	1.00	22	1.00	12	1.00	22	1.00
	-28 to -1 days: 1st dose	*	0.40 (0.09, 1.82)	-	-	*	0.41 (0.09, 1.84)	*	n/a	*	0.37 (0.08, 1.71)
	0 day: 1st dose	0	n/a	*	n/a	*	n/a	*	n/a	*	n/a

	1-7 days: 1st dose	7	8.06 (3.39, 19.14)	7	15.24 (1.65, 140.79)	7	8.33 (3.50, 19.84)	*	n/a	*	n/a
	8-14 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 1 st dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	*	2.05 (0.42, 10.01)	*	n/a	*	2.18 (0.44, 10.64)		n/a	*	1.51 (0.32, 7.23)
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 2nd dose	*	21.52 (6.03, 76.79)	*	n/a	*	26.48 (7.11, 98.58)	*	n/a	*	15.63 (4.50, 54.37)
	8-14 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	1-28 days: 1st dose	9	2.83 (1.28, 6.27)	9	5.32 (0.60, 47.31)	9	3.01 (1.35, 6.70)	*	n/a	-	-
	1-28 days: 2nd dose	*	9.13 (2.50, 33.40)	*	n/a	*	15.25 (3.80, 61.24)	*	n/a	*	6.41 (1.81, 22.74)
Pericarditis											
ChAdOx1 vaccine	Baseline	566	1.00	362	1.00	563	1.00	360	1.00	581	1.00
	-28 to -1 days: 1st dose	64	0.56 (0.43, 0.74)	-	-	64	0.54 (0.41, 0.71)	63	0.53 (0.40, 0.70)	64	0.54 (0.41, 0.71)
	0 day: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 1st dose	17	0.54 (0.33, 0.88)	19	0.56 (0.34, 0.92)	19	0.58 (0.37, 0.93)	19	0.60 (0.37, 0.96)	*	n/a
	8-14 days: 1st dose	32	0.98 (0.68, 1.41)	34	0.94 (0.64, 1.39)	34	1.00 (0.70, 1.43)	33	1.01 (0.70, 1.46)	*	n/a
	15-21 days: 1 st dose	23	0.67 (0.44, 1.02)	23	0.60 (0.38, 0.94)	23	0.64 (0.42, 0.98)	23	0.68 (0.44, 1.04)	*	n/a

	22-28 days: 1st dose	26	0.74 (0.49, 1.10)	26	0.65 (0.43, 0.99)	26	0.70 (0.47, 1.05)	25	0.73 (0.48, 1.11)	*	n/a
	-28 to -1 days: 2nd dose	58	0.44 (0.33, 0.58)	58	0.42 (0.32, 0.57)	58	0.42 (0.32, 0.56)	41	0.41 (0.29, 0.58)	58	0.42 (0.32, 0.56)
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	0.20 (0.03, 1.45)
	1-7 days: 2nd dose	36	1.11 (0.78, 1.57)	37	1.13 (0.80, 1.60)	37	1.11 (0.79, 1.56)	14	0.80 (0.45, 1.41)	37	1.11 (0.78, 1.56)
	8-14 days: 2nd dose	28	0.87 (0.59, 1.29)	29	0.91 (0.61, 1.34)	28	0.86 (0.58, 1.27)	15	1.02 (0.58, 1.77)	29	0.88 (0.60, 1.30)
	15-21 days: 2nd dose	35	1.11 (0.78, 1.57)	36	1.15 (0.81, 1.63)	36	1.12 (0.79, 1.59)	18	1.47 (0.87, 2.49)	36	1.12 (0.79, 1.59)
	22-28 days: 2nd dose	15	0.49 (0.29, 0.83)	15	0.51 (0.30, 0.85)	14	0.46 (0.27, 0.78)	5	0.58 (0.23, 1.45)	15	0.48 (0.29, 0.81)
	1-28 days: 1st dose	98	0.73 (0.58, 0.92)	102	0.69 (0.53, 0.90)	102	0.73 (0.58, 0.92)	100	0.75 (0.59, 0.96)	-	-
	1-28 days: 2nd dose	114	0.90 (0.72, 1.11)	117	0.93 (0.75, 1.17)	115	0.89 (0.72, 1.11)	52	0.96 (0.67, 1.38)	117	0.90 (0.73, 1.12)
BNT162b2 mRNA vaccine	Baseline	407	1.00	268	1.00	402	1.00	208	1.00	414	1.00
	-28 to -1 days: 1st dose	42	0.63 (0.46, 0.88)	-	-	42	0.62 (0.45, 0.86)	38	0.67 (0.47, 0.95)	42	0.61 (0.44, 0.85)
	0 day: 1st dose	*	0.75 (0.19, 3.04)	*	0.54 (0.13, 2.27)	*	0.74 (0.18, 2.97)	*	n/a	*	n/a
	1-7 days: 1st dose	11	0.60 (0.33, 1.09)	11	0.44 (0.22, 0.87)	11	0.58 (0.32, 1.07)	7	0.46 (0.22, 0.99)	*	n/a
	8-14 days: 1st dose	9	0.47 (0.24, 0.92)	9	0.39 (0.19, 0.80)	9	0.46 (0.24, 0.90)	6	0.39 (0.17, 0.88)	*	n/a
	15-21 days: 1 st dose	18	0.95 (0.59, 1.53)	19	0.82 (0.49, 1.39)	18	0.93 (0.57, 1.50)	15	0.95 (0.55, 1.64)	*	n/a
	22-28 days: 1st dose	20	1.04 (0.66, 1.65)	20	0.89 (0.54, 1.46)	20	1.02 (0.64, 1.61)	18	1.11 (0.67, 1.83)	*	n/a
	-28 to -1 days: 2nd dose	35	0.48 (0.34, 0.68)	35	0.45 (0.31, 0.65)	35	0.47 (0.33, 0.67)	31	0.48 (0.32, 0.72)	35	0.45 (0.32, 0.65)

	0 day: 2nd dose	*	1.01 (0.32, 3.15)	*	0.90 (0.29, 2.82)	*	0.99 (0.32, 3.08)	*	1.19 (0.38, 3.75)	*	0.96 (0.31, 3.01)
	1-7 days: 2nd dose	12	0.59 (0.33, 1.06)	12	0.54 (0.30, 0.98)	12	0.58 (0.33, 1.04)	8	0.50 (0.24, 1.02)	12	0.57 (0.32, 1.02)
	8-14 days: 2nd dose	16	0.81 (0.49, 1.35)	16	0.75 (0.45, 1.26)	16	0.80 (0.48, 1.33)	13	0.94 (0.53, 1.69)	16	0.78 (0.47, 1.30)
	15-21 days: 2nd dose	20	1.02 (0.64, 1.61)	21	1.03 (0.65, 1.62)	21	1.06 (0.68, 1.66)	15	1.18 (0.68, 2.06)	21	1.03 (0.66, 1.61)
	22-28 days: 2nd dose	26	1.37 (0.91, 2.05)	26	1.34 (0.89, 2.02)	25	1.31 (0.86, 1.98)	14	1.29 (0.73, 2.29)	26	1.31 (0.87, 1.97)
	1-28 days: 1st dose	58	0.77 (0.58, 1.02)	59	0.65 (0.45, 0.94)	58	0.75 (0.57, 1.00)	46	0.74 (0.53, 1.04)	-	-
	1-28 days: 2nd dose	74	0.94 (0.72, 1.22)	75	0.91 (0.69, 1.19)	74	0.93 (0.71, 1.21)	50	0.93 (0.66, 1.31)	75	0.91 (0.70, 1.19)
mRNA-1273 vaccine	Baseline	12	1.00	*	1.00	11	1.00	5	1.00	12	1.00
	-28 to -1 days: 1st dose	*	1.61 (0.51, 5.04)	-	-	*	1.78 (0.56, 5.66)	*	n/a	*	1.63 (0.52, 5.12)
	0 day: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	-	-
	1-7 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	-	-
	8-14 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	-	-
	15-21 days: 1 st dose	*	n/a	*	n/a	*	n/a	*	n/a	-	-
	22-28 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a	-	-
	-28 to -1 days: 2nd dose	*	n/a								
	0 day: 2nd dose	*	n/a								
	1-7 days: 2nd dose	*	n/a								
	8-14 days: 2nd dose	*	n/a								
	15-21 days: 2nd dose	*	n/a								

	22-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	-	-	*	n/a
	1-28 days: 1st dose	*	1.61 (0.45, 5.85)	*	n/a	*	1.91 (0.52, 7.03)	*	n/a	-	-
	1-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	*	n/a
Cardiac arrhythmia											
ChAdOx1 vaccine	Baseline	116100	1.00	76686	1.00	114543	1.00	68219	1.00	118356	1.00
	-28 to -1 days: 1st dose	17335	0.79 (0.77, 0.80)	-	-	17562	0.78 (0.76, 0.79)	17459	0.78 (0.76, 0.79)	17562	0.77 (0.76, 0.78)
	0 day: 1st dose	278	0.33 (0.29, 0.37)	289	0.34 (0.30, 0.38)	289	0.33 (0.30, 0.37)	283	0.33 (0.29, 0.37)	*	n/a
	1-7 days: 1st dose	5647	0.94 (0.91, 0.96)	5873	0.97 (0.94, 1.00)	5871	0.94 (0.92, 0.97)	5789	0.94 (0.92, 0.97)	*	n/a
	8-14 days: 1st dose	5755	0.92 (0.89, 0.94)	5981	0.95 (0.93, 0.98)	5981	0.93 (0.90, 0.95)	5868	0.92 (0.90, 0.95)	*	n/a
	15-21 days: 1st dose	6022	0.94 (0.92, 0.97)	6243	0.98 (0.95, 1.01)	6242	0.95 (0.92, 0.97)	6109	0.95 (0.92, 0.97)	*	n/a
	22-28 days: 1st dose	5897	0.91 (0.88, 0.93)	6128	0.94 (0.92, 0.97)	6127	0.92 (0.89, 0.94)	5951	0.92 (0.89, 0.94)	*	n/a
	-28 to -1 days: 2nd dose	18474	0.76 (0.74, 0.77)	18595	0.77 (0.76, 0.78)	18595	0.75 (0.74, 0.77)	16213	0.79 (0.78, 0.81)	18595	0.73 (0.71, 0.74)
	0 day: 2nd dose	258	0.29 (0.26, 0.33)	265	0.30 (0.27, 0.34)	265	0.30 (0.26, 0.33)	188	0.29 (0.25, 0.34)	265	0.29 (0.25, 0.32)
	1-7 days: 2nd dose	5126	0.83 (0.81, 0.85)	5236	0.86 (0.84, 0.89)	5223	0.84 (0.82, 0.87)	3859	0.90 (0.87, 0.93)	5236	0.82 (0.79, 0.84)
	8-14 days: 2nd dose	5814	0.95 (0.93, 0.98)	5931	0.99 (0.97, 1.02)	5910	0.97 (0.94, 0.99)	4041	1.04 (1.00, 1.08)	5931	0.94 (0.91, 0.96)
	15-21 days: 2nd dose	5902	0.99 (0.96, 1.01)	6019	1.03 (1.00, 1.06)	6003	1.00 (0.98, 1.03)	3614	1.08 (1.04, 1.12)	6019	0.97 (0.95, 1.00)
	22-28 days: 2nd dose	5699	0.97 (0.95, 1.00)	5833	1.02 (0.99, 1.05)	5809	0.99 (0.97, 1.02)	2819	1.10 (1.06, 1.14)	5833	0.97 (0.94, 0.99)

	1-28 days: 1st dose	23321	0.93 (0.92, 0.95)	24225	0.97 (0.96, 0.99)	24221	0.94 (0.93, 0.96)	23717	0.94 (0.93, 0.96)	-	-	
	1-28 days: 2nd dose	22541	0.93 (0.92, 0.95)	23019	0.98 (0.96, 0.99)	22945	0.95 (0.93, 0.96)	14333	1.01 (0.99, 1.03)	23019	0.92 (0.91, 0.94)	
BNT162b2 mRNA vaccine	Baseline	111705	1.00	89382	1.00	110087	1.00	55351	1.00	113968	1.00	
	-28 to -1 days: 1st dose	12627	0.73 (0.71, 0.74)	-	-	12767	0.72 (0.71, 0.73)	11805	0.73 (0.72, 0.75)	12767	0.72 (0.71, 0.74)	
	0 day: 1st dose	223	0.32 (0.28, 0.37)	232	0.30 (0.26, 0.34)	232	0.33 (0.29, 0.37)	215	0.34 (0.30, 0.39)	0	n/a	
	1-7 days: 1st dose	3775	0.77 (0.75, 0.80)	3958	0.73 (0.70, 0.75)	3956	0.79 (0.76, 0.81)	3642	0.82 (0.79, 0.84)	0	n/a	
	8-14 days: 1st dose	4613	0.91 (0.88, 0.93)	4837	0.88 (0.85, 0.91)	4834	0.92 (0.90, 0.95)	4452	0.95 (0.92, 0.98)	0	n/a	
	15-21 days: 1 st dose	4787	0.92 (0.89, 0.95)	4971	0.91 (0.88, 0.94)	4960	0.93 (0.90, 0.95)	4625	0.96 (0.93, 0.99)	0	n/a	
	22-28 days: 1st dose	4429	0.88 (0.86, 0.91)	4593	0.89 (0.86, 0.92)	4582	0.89 (0.86, 0.92)	4247	0.92 (0.89, 0.95)	0	n/a	
	-28 to -1 days: 2nd dose	14913	0.76 (0.74, 0.77)	15010	0.74 (0.73, 0.76)	15010	0.75 (0.74, 0.77)	14499	0.82 (0.80, 0.84)	15010	0.73 (0.71, 0.74)	
	0 day: 2nd dose	255	0.33 (0.29, 0.37)	257	0.32 (0.28, 0.36)	257	0.33 (0.29, 0.37)	244	0.35 (0.31, 0.40)	257	0.31 (0.28, 0.36)	
	1-7 days: 2nd dose	4619	0.85 (0.82, 0.87)	4737	0.84 (0.81, 0.87)	4712	0.86 (0.83, 0.88)	4405	0.93 (0.90, 0.96)	4737	0.83 (0.80, 0.85)	
	8-14 days: 2nd dose	5158	0.94 (0.91, 0.96)	5288	0.94 (0.91, 0.97)	5257	0.95 (0.92, 0.98)	4708	1.05 (1.01, 1.08)	5288	0.92 (0.89, 0.95)	
	15-21 days: 2nd dose	5365	0.98 (0.95, 1.01)	5495	0.98 (0.96, 1.01)	5477	0.99 (0.97, 1.02)	4716	1.10 (1.06, 1.13)	5495	0.96 (0.94, 0.99)	
	22-28 days: 2nd dose	5281	0.97 (0.95, 1.00)	5427	0.99 (0.96, 1.01)	5409	0.99 (0.97, 1.02)	4393	1.11 (1.07, 1.14)	5427	0.96 (0.94, 0.99)	
		1-28 days: 1st dose	17604	0.88 (0.86, 0.89)	18359	0.87 (0.85, 0.89)	18332	0.89 (0.87, 0.91)	16966	0.92 (0.91, 0.94)	-	-
	1-28 days: 2nd dose	20423	0.94 (0.92, 0.95)	20947	0.94 (0.93, 0.96)	20855	0.95 (0.94, 0.97)	18222	1.04 (1.02, 1.06)	20947	0.92 (0.91, 0.94)	

mRNA-1273 vaccine	Baseline	1221	1.00	123	1.00	1193	1.00	557	1.00	1221	1.00	
	-28 to -1 days: 1st dose	184	0.89 (0.77, 1.05)	-	-	184	0.91 (0.78, 1.06)	73	0.92 (0.72, 1.19)	184	0.90 (0.77, 1.05)	
	0 day: 1st dose	9	1.31 (0.68, 2.52)	9	1.08 (0.54, 2.14)	9	1.34 (0.69, 2.58)	*	0.61 (0.09, 4.34)	0	n/a	
	1-7 days: 1st dose	38	0.79 (0.57, 1.10)	38	0.67 (0.46, 0.98)	38	0.82 (0.59, 1.13)	6	0.58 (0.26, 1.31)	0	n/a	
	8-14 days: 1st dose	40	0.87 (0.63, 1.19)	40	0.73 (0.51, 1.06)	39	0.88 (0.64, 1.22)	11	1.31 (0.71, 2.42)	0	n/a	
	15-21 days: 1 st dose	43	1.01 (0.74, 1.37)	43	0.83 (0.58, 1.19)	43	1.07 (0.78, 1.45)	5	0.73 (0.30, 1.79)	0	n/a	
	22-28 days: 1st dose	35	0.89 (0.63, 1.24)	35	0.73 (0.50, 1.07)	34	0.92 (0.65, 1.30)	5	1.25 (0.51, 3.10)	0	n/a	
	-28 to -1 days: 2nd dose	38	0.65 (0.47, 0.91)	38	0.59 (0.39, 0.89)	38	0.67 (0.48, 0.93)	*	n/a	38	0.66 (0.47, 0.92)	
	0 day: 2nd dose	1	0.55 (0.08, 3.90)	1	0.49 (0.07, 3.54)	0	n/a	*	n/a	1	0.56 (0.08, 3.99)	
	1-7 days: 2nd dose	22	1.88 (1.23, 2.90)	22	1.68 (1.02, 2.76)	21	2.10 (1.35, 3.26)	*	n/a	22	1.93 (1.25, 2.97)	
	8-14 days: 2nd dose	13	1.36 (0.78, 2.36)	13	1.20 (0.65, 2.20)	11	1.49 (0.82, 2.73)	*	n/a	13	1.39 (0.80, 2.42)	
	15-21 days: 2nd dose	6	0.82 (0.37, 1.84)	6	0.72 (0.31, 1.67)	6	1.22 (0.54, 2.75)	*	n/a	6	0.84 (0.37, 1.89)	
	22-28 days: 2nd dose	7	1.39 (0.66, 2.95)	7	1.20 (0.54, 2.64)	6	2.14 (0.95, 4.86)	*	n/a	7	1.42 (0.67, 3.02)	
	1-28 days: 1st dose	156	0.89 (0.75, 1.05)	156	0.74 (0.57, 0.95)	154	0.92 (0.77, 1.09)	27	0.90 (0.60, 1.36)	-	-	
	1-28 days: 2nd dose	48	1.43 (1.06, 1.93)	48	1.26 (0.85, 1.87)	44	1.75 (1.27, 2.41)	*	n/a	48	1.46 (1.08, 1.98)	

*Sensitivity 1: excluding those who died from the outcome; Sensitivity 2: restricting analysis to the period post-vaccination, without censoring at death, Sensitivity 3: restricting the study period until the 1 August 2021, Sensitivity 4: restricting the study period until the 17 May 2021, when CDC announced cases of myocarditis after BNT162b2 vaccine, Sensitivity 5: removing patients who had outcomes in the 28 days after 1 dose, but before second dose.

Supplementary table 8b: Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to vaccination, adjusted for calendar time from December 1 2020 to August 24 2021. Comparisons between different sensitivity analyses (cells with < 5 are suppressed) to compare different choices of pre-risk length.

		Main		Sensitivity 6*		Sensitivity 7*		Sensitivity 8*	
		events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)	events	IRR (95% CI)
Myocarditis									
ChAdOx1 vaccine	Baseline	550	1.00	689	1.00	649	1.00	366	1.00
	-28 to -1 days: 1st dose	81	0.74 (0.58, 0.95)	-	-	22	0.42 (0.28, 0.65)	208	0.94 (0.77, 1.14)
	0 day: 1st dose	*	0.54 (0.14, 2.19)	*	0.61 (0.15, 2.45)	*	0.54 (0.13, 2.16)	*	0.56 (0.14, 2.27)
	1-7 days: 1st dose	47	1.76 (1.29, 2.42)	47	1.97 (1.45, 2.69)	47	1.75 (1.28, 2.39)	47	1.82 (1.31, 2.53)
	8-14 days: 1st dose	35	1.22 (0.85, 1.74)	35	1.36 (0.96, 1.94)	35	1.21 (0.85, 1.73)	35	1.25 (0.87, 1.82)
	15-21 days: 1 st dose	30	1.03 (0.71, 1.51)	30	1.15 (0.79, 1.68)	30	1.03 (0.71, 1.50)	30	1.06 (0.71, 1.57)
	22-28 days: 1st dose	30	1.03 (0.71, 1.51)	30	1.15 (0.79, 1.68)	30	1.03 (0.71, 1.50)	30	1.05 (0.71, 1.56)
	-28 to -1 days: 2nd dose	58	0.65 (0.49, 0.87)	-	-	18	0.41 (0.25, 0.65)	115	0.78 (0.61, 1.00)
	0 day: 2nd dose	*	0.64 (0.16, 2.56)	*	0.71 (0.18, 2.86)	*	0.64 (0.16, 2.56)	*	0.65 (0.16, 2.60)
	1-7 days: 2nd dose	13	0.60 (0.34, 1.04)	13	0.67 (0.38, 1.16)	13	0.60 (0.34, 1.04)	13	0.61 (0.35, 1.07)
	8-14 days: 2nd dose	28	1.31 (0.88, 1.93)	28	1.45 (0.99, 2.14)	28	1.31 (0.89, 1.94)	28	1.33 (0.89, 1.98)
	15-21 days: 2nd dose	19	0.91 (0.57, 1.45)	19	1.00 (0.63, 1.59)	19	0.91 (0.57, 1.45)	19	0.92 (0.58, 1.48)
	22-28 days: 2nd dose	24	1.16 (0.76, 1.76)	24	1.27 (0.84, 1.93)	24	1.16 (0.76, 1.76)	24	1.18 (0.77, 1.81)
	1-28 days: 1st dose	142	1.29 (1.05, 1.58)	142	1.45 (1.19, 1.76)	142	1.29 (1.05, 1.57)	142	1.32 (1.05, 1.66)
	1-28 days: 2nd dose	84	1.00 (0.78, 1.27)	84	1.10 (0.87, 1.41)	84	1.00 (0.78, 1.28)	84	1.01 (0.78, 1.31)
	Baseline	398	1.00	495	1.00	460	1.00	308	1.00

BNT162b2 mRNA vaccine	-28 to -1 days: 1st dose	49	0.75 (0.55, 1.01)	-	-	16	0.48 (0.29, 0.79)	110	0.87 (0.69, 1.10)
	0 day: 1st dose	*	1.24 (0.40, 3.88)	*	1.31 (0.42, 4.08)	*	1.22 (0.39, 3.80)	*	1.26 (0.40, 3.93)
	1-7 days: 1st dose	27	1.45 (0.97, 2.17)	27	1.52 (1.02, 2.27)	27	1.42 (0.96, 2.12)	27	1.47 (0.98, 2.21)
	8-14 days: 1st dose	23	1.23 (0.80, 1.90)	23	1.29 (0.84, 1.98)	23	1.21 (0.79, 1.86)	23	1.25 (0.81, 1.93)
	15-21 days: 1 st dose	21	1.14 (0.73, 1.78)	21	1.19 (0.76, 1.86)	21	1.12 (0.72, 1.75)	21	1.15 (0.73, 1.80)
	22-28 days: 1st dose	23	1.33 (0.86, 2.04)	23	1.39 (0.91, 2.13)	23	1.30 (0.85, 2.00)	23	1.33 (0.86, 2.06)
	-28 to -1 days: 2nd dose	48	0.96 (0.70, 1.32)	-	-	19	0.73 (0.46, 1.17)	77	0.94 (0.71, 1.25)
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 2nd dose	23	1.75 (1.13, 2.70)	23	1.87 (1.22, 2.86)	23	1.72 (1.12, 2.65)	23	1.73 (1.11, 2.69)
	8-14 days: 2nd dose	15	1.16 (0.69, 1.97)	15	1.24 (0.74, 2.10)	15	1.15 (0.68, 1.93)	15	1.15 (0.68, 1.96)
	15-21 days: 2nd dose	14	1.14 (0.66, 1.97)	14	1.23 (0.71, 2.10)	14	1.13 (0.66, 1.94)	14	1.14 (0.66, 1.97)
	22-28 days: 2nd dose	12	1.01 (0.57, 1.82)	12	1.08 (0.61, 1.94)	12	1.00 (0.56, 1.79)	12	1.01 (0.56, 1.82)
				-	-				
		1-28 days: 1st dose	94	1.31 (1.03, 1.66)	94	1.38 (1.10, 1.74)	94	1.29 (1.02, 1.63)	94
	1-28 days: 2nd dose	64	1.30 (0.98, 1.72)	64	1.38 (1.05, 1.82)	64	1.27 (0.96, 1.68)	64	1.29 (0.96, 1.73)
mRNA-1273 vaccine	Baseline	22	1.00	26	1.00	24	1.00	19	1.00
	-28 to -1 days: 1st dose	*	0.41 (0.09, 1.87)	-	-	*	n/a	5	0.56 (0.20, 1.56)
	0 day: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 1st dose	7	8.38 (3.53, 19.91)	7	8.71 (3.74, 20.27)	7	8.81 (3.74, 20.72)	7	7.88 (3.24, 19.14)
	8-14 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 1 st dose	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a

	-28 to -1 days: 2nd dose	*	2.19 (0.45, 10.69)	-	-	*	4.85 (1.00, 23.55)	*	1.45 (0.29, 7.32)
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 2nd dose	*	23.10 (6.46, 82.56)	*	20.96 (6.22, 70.69)	*	25.41 (7.17, 90.06)	*	20.33 (5.55, 74.43)
	8-14 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-28 days: 1st dose	9	2.97 (1.34, 6.58)	9	3.02 (1.39, 6.53)	9	3.09 (1.41, 6.76)	9	2.80 (1.23, 6.37)
	1-28 days: 2nd dose	*	9.84 (2.69, 36.03)	*	8.82 (2.55, 30.47)	*	10.77 (2.97, 39.12)	*	8.76 (2.34, 32.82)
Positive SARS-CoV-2 test	Baseline	119	1.00	151	1.00	123	1.00	110	1.00
	-28 to -1 days: positive test	32	2.84 (1.89, 4.28)	-	-	28	4.72 (3.08, 7.21)	41	2.47 (1.68, 3.65)
	0 day: positive test	36	78.21 (52.90, 115.61)	36	66.92 (45.92, 97.52)	36	78.39 (53.20, 115.50)	36	83.72 (56.29, 124.52)
	1-7 days: positive test	68	21.08 (15.34, 28.96)	68	18.00 (13.32, 24.31)	68	20.81 (15.20, 28.49)	68	22.44 (16.22, 31.04)
	8-14 days: positive test	37	11.29 (7.70, 16.57)	37	9.62 (6.64, 13.94)	37	11.06 (7.56, 16.18)	37	11.88 (8.06, 17.52)
	15-21 days: positive test	18	5.36 (3.24, 8.89)	18	4.56 (2.78, 7.49)	18	5.35 (3.24, 8.85)	18	5.58 (3.35, 9.27)
	22-28 days: positive test	11	3.08 (1.65, 5.75)	11	2.64 (1.42, 4.89)	11	3.11 (1.67, 5.81)	11	3.17 (1.69, 5.94)
	1-28 days: positive test	134	9.76 (7.51, 12.69)	134	8.38 (6.56, 10.71)	134	9.73 (7.51, 12.62)	134	10.16 (7.76, 13.31)
Pericarditis									

	-28 to -1 days: 2nd dose	35	0.47 (0.33, 0.67)	-	-	15	0.43 (0.26, 0.73)	76	0.60 (0.46, 0.80)
	0 day: 2nd dose	*	0.99 (0.32, 3.09)	*	1.23 (0.40, 3.85)	*	1.09 (0.35, 3.39)	*	0.96 (0.30, 2.99)
	1-7 days: 2nd dose	12	0.58 (0.33, 1.04)	12	0.73 (0.41, 1.29)	12	0.64 (0.36, 1.14)	12	0.57 (0.31, 1.02)
	8-14 days: 2nd dose	16	0.80 (0.48, 1.32)	16	0.98 (0.59, 1.63)	16	0.87 (0.52, 1.44)	16	0.78 (0.47, 1.30)
	15-21 days: 2nd dose	21	1.05 (0.67, 1.64)	21	1.29 (0.83, 2.01)	21	1.14 (0.73, 1.78)	21	1.03 (0.65, 1.62)
	22-28 days: 2nd dose	26	1.34 (0.89, 2.02)	26	1.63 (1.09, 2.44)	26	1.45 (0.97, 2.17)	26	1.32 (0.88, 2.00)
	1-28 days: 1st dose	59	0.77 (0.58, 1.02)	59	0.90 (0.68, 1.19)	59	0.81 (0.61, 1.08)	59	0.73 (0.55, 0.98)
	1-28 days: 2nd dose	75	0.93 (0.72, 1.21)	75	1.15 (0.89, 1.48)	75	1.02 (0.79, 1.31)	75	0.91 (0.70, 1.20)
mRNA-1273 vaccine	Baseline	12	1.00	17	1.00	17	1.00	10	1.00
	-28 to -1 days: 1st dose	*	1.62 (0.52, 5.07)	-	-	*	n/a	6	1.14 (0.41, 3.19)
	0 day: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	8-14 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 1 st dose	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 1st dose	*	n/a	*	n/a	*	n/a	*	n/a
	-28 to -1 days: 2nd dose	*	n/a	-	-	*	n/a	*	n/a
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	1-7 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	8-14 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	15-21 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
	22-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a

	1-28 days: 1st dose	*	1.64 (0.45, 5.94)	*	1.33 (0.39, 4.59)	*	1.21 (0.35, 4.22)	*	1.57 (0.42, 5.88)
	1-28 days: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a
Positive SARS-CoV-2 test	Baseline	95	1.00	124	1.00	104	1.00	88	1.00
	-28 to -1 days: positive test	29	3.57 (2.30, 5.55)	-	-	20	4.45 (2.71, 7.30)	36	2.78 (1.82, 4.25)
	0 day: positive test	11	35.04 (18.47, 66.46)	11	29.80 (15.92, 55.77)	11	33.25 (17.62, 62.73)	11	38.67 (20.30, 73.67)
	1-7 days: positive test	11	4.85 (2.56, 9.18)	11	4.10 (2.19, 7.66)	11	4.53 (2.40, 8.52)	11	5.30 (2.79, 10.06)
	8-14 days: positive test	9	3.81 (1.90, 7.63)	9	3.18 (1.60, 6.30)	9	3.53 (1.77, 7.05)	9	4.05 (2.01, 8.14)
	15-21 days: positive test	*	1.63 (0.59, 4.45)	*	1.35 (0.50, 3.66)	*	1.52 (0.56, 4.15)	*	1.67 (0.61, 4.58)
	22-28 days: positive test	*	1.15 (0.36, 3.66)	*	0.95 (0.30, 3.00)	*	1.09 (0.35, 3.46)	*	1.16 (0.37, 3.69)
	1-28 days: positive test	27	2.79 (1.80, 4.32)	27	2.33 (1.52, 3.56)	27	2.61 (1.69, 4.03)	27	2.91 (1.87, 4.53)
	Cardiac arrhythmia								
ChAdOx1 vaccine	Baseline	118356	1.00	154513	1.00	139316	1.00	80393	1.00
	-28 to -1 days: 1st dose	17562	0.78 (0.76, 0.79)	-	-	7311	0.65 (0.63, 0.67)	40103	0.88 (0.87, 0.90)
	0 day: 1st dose	289	0.33 (0.30, 0.38)	289	0.37 (0.33, 0.42)	289	0.34 (0.30, 0.38)	289	0.33 (0.29, 0.37)
	1-7 days: 1st dose	5873	0.94 (0.92, 0.97)	5873	1.05 (1.03, 1.08)	5873	0.96 (0.94, 0.99)	5873	0.92 (0.90, 0.95)
	8-14 days: 1st dose	5981	0.93 (0.90, 0.95)	5981	1.03 (1.00, 1.05)	5981	0.95 (0.92, 0.97)	5981	0.90 (0.88, 0.93)
	15-21 days: 1 st dose	6243	0.95 (0.92, 0.97)	6243	1.05 (1.02, 1.07)	6243	0.97 (0.95, 1.00)	6243	0.92 (0.89, 0.94)
	22-28 days: 1st dose	6128	0.92 (0.89, 0.94)	6128	1.01 (0.98, 1.04)	6128	0.94 (0.92, 0.97)	6128	0.88 (0.86, 0.91)
	-28 to -1 days: 2nd dose	18595	0.75 (0.74, 0.77)	-	-	7886	0.65 (0.63, 0.66)	34017	0.81 (0.80, 0.82)

	1-28 days: 1st dose	18359	0.89 (0.87, 0.90)	18359	0.99 (0.98, 1.01)	18359	0.92 (0.90, 0.93)	18359	0.85 (0.84, 0.87)	
	1-28 days: 2nd dose	20947	0.95 (0.93, 0.96)	20947	1.06 (1.04, 1.08)	20947	0.98 (0.96, 0.99)	20947	0.92 (0.90, 0.93)	
mRNA-1273 vaccine	Baseline	1221	1.00	1443	1.00	1346	1.00	929	1.00	
	-28 to -1 days: 1st dose	184	0.90 (0.77, 1.05)	-	-	78	0.78 (0.62, 0.98)	457	1.17 (1.04, 1.31)	
	0 day: 1st dose	9	1.32 (0.69, 2.54)	9	1.31 (0.68, 2.53)	9	1.30 (0.68, 2.51)	9	1.45 (0.75, 2.80)	
	1-7 days: 1st dose	38	0.80 (0.58, 1.11)	38	0.79 (0.57, 1.10)	38	0.79 (0.57, 1.10)	38	0.89 (0.64, 1.23)	
	8-14 days: 1st dose	40	0.88 (0.64, 1.21)	40	0.86 (0.63, 1.18)	40	0.87 (0.63, 1.19)	40	0.97 (0.71, 1.33)	
	15-21 days: 1 st dose	43	1.02 (0.75, 1.38)	43	0.99 (0.73, 1.35)	43	1.01 (0.74, 1.37)	43	1.13 (0.83, 1.53)	
	22-28 days: 1st dose	35	0.90 (0.64, 1.26)	35	0.87 (0.62, 1.22)	35	0.89 (0.63, 1.25)	35	1.00 (0.71, 1.40)	
	-28 to -1 days: 2nd dose	38	0.66 (0.47, 0.92)	-	-	19	0.68 (0.43, 1.08)	57	0.81 (0.61, 1.08)	
	0 day: 2nd dose	*	n/a	*	n/a	*	n/a	*	n/a	
	1-7 days: 2nd dose	22	1.93 (1.25, 2.96)	22	1.86 (1.21, 2.86)	22	1.92 (1.25, 2.94)	22	2.16 (1.40, 3.32)	
	8-14 days: 2nd dose	13	1.39 (0.80, 2.42)	13	1.34 (0.77, 2.33)	13	1.38 (0.80, 2.40)	13	1.55 (0.89, 2.71)	
	15-21 days: 2nd dose	6	0.84 (0.37, 1.89)	6	0.81 (0.36, 1.82)	6	0.84 (0.37, 1.88)	6	0.94 (0.42, 2.12)	
	22-28 days: 2nd dose	7	1.43 (0.67, 3.03)	7	1.38 (0.65, 2.93)	7	1.42 (0.67, 3.01)	7	1.60 (0.75, 3.40)	
		1-28 days: 1st dose	156	0.90 (0.76, 1.06)	156	0.88 (0.74, 1.04)	156	0.89 (0.75, 1.05)	156	0.99 (0.83, 1.18)
		1-28 days: 2nd dose	48	1.46 (1.08, 1.98)	48	1.41 (1.05, 1.90)	48	1.45 (1.08, 1.96)	48	1.63 (1.20, 2.21)
Positive SARS-CoV-2 test	Baseline	15119	1.00	21737	1.00	17222	1.00	13499	1.00	
	-28 to -1 days: positive test	6618	4.82 (4.68, 4.97)	-	-	4515	5.65 (5.46, 5.84)	8238	4.11 (3.99, 4.23)	
	0 day: positive test	3847	69.83 (67.32, 72.43)	3847	52.74 (50.93, 54.62)	3847	63.41 (61.17, 65.73)	3847	78.58 (75.71, 81.56)	

1-7 days: positive test	4593	11.73 (11.33, 12.14)	4593	8.82 (8.54, 9.11)	4593	10.53 (10.18, 10.88)	4593	13.09 (12.64, 13.55)
8-14 days: positive test	2643	6.57 (6.30, 6.85)	2643	4.90 (4.71, 5.11)	2643	5.80 (5.56, 6.05)	2643	7.19 (6.89, 7.50)
15-21 days: positive test	966	2.30 (2.15, 2.45)	966	1.71 (1.61, 1.83)	966	2.05 (1.92, 2.18)	966	2.47 (2.31, 2.64)
22-28 days: positive test	738	1.67 (1.55, 1.80)	738	1.25 (1.16, 1.34)	738	1.51 (1.41, 1.63)	738	1.76 (1.64, 1.90)
1-28 days: positive test	8940	5.35 (5.21, 5.50)	8940	4.03 (3.93, 4.13)	8940	4.80 (4.68, 4.93)	8940	5.79 (5.63, 5.95)

*Sensitivity 6: including pre-risk into baseline; Sensitivity 7: restricting pre-risk to two weeks; Sensitivity 8: increasing pre-risk to 8 weeks.

Supplementary table 9: Age distribution of vaccinated patients with each outcome in the study period and in the period restricted until the 17 May 20201.

	Myocarditis					
	ChAdOx1		BNT162b2		mRNA-1273	
	<i>Complete study period</i>	<i>Restricted to 17 May 2021</i>	<i>Complete study period</i>	<i>Restricted to 17 May 2021</i>	<i>Complete study period</i>	<i>Restricted to 17 May 2021</i>
Number of patients	919	898	657	504	39	8
Age						
Mean age (SD)	57 (45, 70)	57 (45, 70)	58 (36, 74)	64 (51, 77)	30 (22, 38)	41 (28, 47)
16-29 years	7.3 (67)	7.2 (65)	14.0 (92)	6.3 (32)	48.7 (19)	*
30-39 years	9.0 (83)	9.1 (82)	15.7 (103)	7.5 (38)	30.8 (12)	*
40+ years	83.7 (769)	83.6 (751)	70.2 (461)	86.1 (434)	20.5 (8)	62.5 (5)

Supplementary table 10: Measures of effect of vaccinations and SARS-CoV-2 infections presented in absolute terms, number needed to expose for one excess event; excess events due to exposure; excess events per 1 million exposed. Only significant increased risks were

reported over the 1-28 days post exposure. When IRR were not significant over the 1-28 days post-vaccine, absolute measures were not given.

	IRR (95% CI) 1-28 days*	Number needed to expose to cause one excess event (95% CI)	Excess events per 1,000,000 exposed (95% CI)
Myocarditis			
with 1st dose of ChAdOx1	1.29 (1.05, 1.58)	649,082 (394,227 – 3,157,549)	2 (0, 3)
with 2nd dose of ChAdOx1	1.00 (0.78, 1.27)	-	-
with 1st dose of BNT162b2	1.31 (1.03, 1.66)	760577 (453,568 – 5,353,966)	1 (0, 2)
with 2nd dose of BNT162b2	1.30 (0.98, 1.72)	-	-
with 1st dose of mRNA-1273	2.97 (1.34, 6.58)	168,612 (131,832 – 442,126)	6 (2, 8)
with 2nd dose of mRNA-1273	9.84 (2.69, 36.03)	102,625 (94,830 – 146,797)	10 (7, 11)
with SARS-CoV-2 infection	9.76 (7.51, 12.69)	25,183 (24,537 – 26,077)	40 (38, 41)
Myocarditis (< 40)			
with 1st dose of ChAdOx1	0.92 (0.55, 1.55)	-	-
with 2nd dose of ChAdOx1	1.50 (0.88, 2.55)	-	-
with 1st dose of BNT162b2	1.83 (1.20, 2.79)	549,501 (388,931 – 1,479,310)	2 (1, 3)
with 2nd dose of BNT162b2	3.40 (1.91, 6.04)	292,742 (247,620 – 432,998)	3 (2, 4)
with 1st dose of mRNA-1273	3.89 (1.60, 9.44)	131,834 (109,515 – 261,052)	8 (4, 9)
with 2nd dose of mRNA-1273	20.71 (4.02, 106.68)	65,423 (62,853 – 82,867)	15 (12, 16)
with SARS-CoV-2 infection	4.06 (2.21, 7.45)	102,479 (89,197 – 141,044)	10 (7, 11)
Pericarditis			
with 1st dose of ChAdOx1	0.74 (0.59, 0.92)	-	-
with 2nd dose of ChAdOx1	0.91 (0.73, 1.13)	-	-
with 1st dose of BNT162b2	0.77 (0.58, 1.02)	-	-
with 2nd dose of BNT162b2	0.93 (0.72, 1.21)	-	-
with 1st dose of mRNA-1273	1.64 (0.45, 5.94)	-	-
with 2nd dose of mRNA-1273	n/a	-	-
with SARS-CoV-2 infection	2.79 (1.80, 4.32)	174,970 (145,934 – 253,102)	6 (4, 7)
Cardiac arrhythmia			
with 1st dose of ChAdOx1	0.94 (0.93, 0.96)	-	-
with 2nd dose of ChAdOx1	0.95 (0.94, 0.96)	-	-
with 1st dose of BNT162b2	0.89 (0.87, 0.90)	-	-

with 2nd dose of BNT162b2	0.95 (0.93, 0.96)	-	-
with 1st dose of BNT162b2	0.90 (0.76, 1.06)	-	-
with 2nd dose of mRNA-1273	1.46 (1.08, 1.98)	24,335 (15,547 – 103,369)	41 (10, 64)
with SARS-CoV-2 infection	5.35 (5.21, 5.50)	416 (414 - 419)	2400 (2385, 2415)

Supplementary table 11: ICD-10 codes used to identify cases with each outcome.

Composite outcomes	ICD-10 code and description
Myocarditis	I40 - Acute myocarditis I400 - Infective myocarditis I401 - Isolated myocarditis I408 - Other acute myocarditis I409 - Acute myocarditis, unspecified I41 - Myocarditis in diseases classified elsewhere I410 - Myocarditis in bacterial diseases classified elsewhere I411 - Myocarditis in viral diseases classified elsewhere I412 - Myocarditis in other infectious and parasitic diseases classified elsewhere I418 - Myocarditis in other diseases classified elsewhere I514 - Myocarditis, unspecified
Pericarditis	I010 - Acute rheumatic pericarditis I092 - Chronic rheumatic pericarditis I30 - Acute pericarditis I300 - Acute nonspecific idiopathic pericarditis I301 - Infective pericarditis I308 - Other forms of acute pericarditis I309 - Acute pericarditis, unspecified I310 - Chronic adhesive pericarditis I311 - Chronic constrictive pericarditis I32 - Pericarditis in diseases classified elsewhere

	<p>I320 - Pericarditis in bacterial diseases classified elsewhere I321 - Pericarditis in other infectious and parasitic diseases classified elsewhere I328 - Pericarditis in other diseases classified elsewhere</p>
Cardiac arrhythmia	
Atrial fibrillation and flutter	<p>I48 - Atrial fibrillation and flutter I480 - Paroxysmal atrial fibrillation I481 - Persistent atrial fibrillation I482 - Chronic atrial fibrillation I483 - Typical atrial flutter I484 - Atypical atrial flutter I489 - Atrial fibrillation and atrial flutter, unspecified I48X - Atrial fibrillation and flutter I471 - Supraventricular tachycardia</p>
AV block and conduction disorders	<p>I44 - Atrioventricular and left bundle-branch block I440 - Atrioventricular block, first degree I441 - Atrioventricular block, second degree I442 - Atrioventricular block, complete I443 - Other and unspecified atrioventricular block I444 - Left anterior fascicular block I445 - Left posterior fascicular block I446 - Other and unspecified fascicular block I447 - Left bundle-branch block, unspecified I45 - Other conduction disorders I450 - Right fascicular block I451 - Other and unspecified right bundle-branch block I452 - Bifascicular block I453 - Trifascicular block I454 - Nonspecific intraventricular block I455 - Other specified heart block I458 - Other specified conduction disorders I459 - Conduction disorder, unspecified</p>

Ventricular tachycardia	I47 - Paroxysmal tachycardia I470 - Re-entry ventricular arrhythmia I472 - Ventricular tachycardia I479 - Paroxysmal tachycardia, unspecified
Ventricular fibrillation	I490 - Ventricular fibrillation and flutter
Other cardiac cardiac arrhythmias	I456 - Pre-excitation syndrome I49 - Other cardiac arrhythmias I491 - Atrial premature depolarization I492 - Junctional premature depolarization I493 - Ventricular premature depolarization I494 - Other and unspecified premature depolarization I495 - Sick sinus syndrome I498 - Other specified cardiac arrhythmias I499 - Cardiac arrhythmia, unspecified R00 - Abnormalities of heart beat R000 - Tachycardia, unspecified R001 - Bradycardia, unspecified R002 - Palpitations R008 - Other and unspecified abnormalities of heart beat
Coeliac	K900 - Coeliac disease
Anaphylaxis	T780 - Anaphylactic shock due to adverse food reaction T782 - Anaphylactic shock, unspecified T805 - Anaphylactic shock due to serum T886 - Anaphylactic shock due to adverse effect of correct drug or medicament properly administered

